Patent Grant
12122778
This disclosure relates to novel chemical compositions for activating pyruvate kinase (PKR).
Pyruvate Kinase (PK) converts phosphoenolpyruvate (PEP) and adenosine diphosphate (ADP) to pyruvate and adenosine triphosphate (ATP), respectively, which is the final step in glycolysis. In humans, four PK isoforms are expressed by two structural genes. The PKLR gene encodes PKR and PKL, tissue specific isoforms expressed in erythroid cells and liver cells, respectively. The PKM gene codes for isoforms PKM1, expressed in brain and skeletal muscle, and PKM2 (M2-type pyruvate kinase), expressed in fetal and most adult tissues except erythroid cells.
Mutations in the PKLR gene can lead to pyruvate kinase deficiency (PKD), an autosomal recessive disorder, which is the most frequent enzymatic defect of the glycolytic pathway in erythrocytes. Over 200 different mutations have been identified on the structural PKLR gene. Generally, most PKD patients are heterozygous with two different mutant alleles, but homozygous mutations have also been described. Clinical symptoms of PKD vary considerably from mild to severe anemia. Mutations can reduce PK enzymatic activity or decrease PK protein stability. Pathological manifestations are usually observed when enzyme activity falls below 25% normal PK activity, and severe disease has been associated with a high degree of reticulocytosis. Although the global incidence of PKD is unknown, it has been estimated at 51 cases per million in North America.
Currently, there is no definitive treatment for severe PKD. Although splenectomy can be clinically useful in patients with severe disease, in some cases, allogeneic hematopoietic transplantation is required. In these patients, hematopoietic stem cell (HSC) gene therapy might be a good and more effective treatment. Gene therapy strategies for PKD have been addressed in animal models demonstrating that introduction of the correct version of the human PKLR gene into hematopoietic stem cells using retroviral vectors alleviates the disease. Although bone marrow transplant (BMT) or gene therapy strategies would be definitive treatments of the disease, they have yet to be realized clinically, and important adverse effects are associated with both approaches.
There remains a need for strategies to improve the treatment of diseases related to PKR, such as PKD, including the discovery and development of PKR activating small molecules. PKR exists in both a dimeric and tetrameric state, but functions most efficiently as a tetramer. Small molecules have been shown to be capable of shifting the equilibrium of PKR to the tetrameric (most active) form, providing a mechanistic rationale for their use as therapy for PKD-associated hemolytic anemia. Thus, there is a need for PKR activating compounds, useful for treating diseases and disorders associated with modulation of PKR and/or PKM2.
The disclosure relates in part to compounds and compositions useful for activating PKR, including the discovery of a novel compound active with wild type (wt) PKR and/or mutant isozyme forms of PKR. For example, compounds and methods provided herein can be used for activating wild type PKR isozyme and/or a mutant PKR isozyme. Examples of mutant PKR isozyme include G332S, G364D, T384M, G37E, R479H, R479K, R486W, R532W, R510Q, I90N, and R490W. The invention is based in part on the discovery of a novel compound demonstrating activation of (wt) PKR and the G332S and R510Q mutant forms of PKR.
A method for treating pyruvate kinase deficiency (PKD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of: (a) compound of Formula (I) or a pharmaceutically acceptable salt thereof, (b) a composition comprising a compound of Formula (I) or a salt thereof and a carrier; or (c) a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, to thereby treat PKD in the subject. The method can include or result in activating one or more isozymes of pyruvate kinase. One or more isozymes of pyruvate kinase can be selected from PKR, PKM2, and PKL; the method can also include or result in activating a mutant PKR isozyme.
One aspect of this invention relates to compounds of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Another aspect of this invention relates to compounds of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
Another aspect of this invention relates to compounds of Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
Another aspect of this invention relates to compounds of Formula IV:
or a pharmaceutically acceptable salt thereof, wherein:
Another aspect of this invention relates to compounds of Formula I, II, III, or IV that are PKR Activating Compounds. In some embodiments, a PKR Activating Compound as used herein refers to a compound having one or more of the following characteristics when tested according to the Luminescence Assay Protocol of Example 24 below: (1) an AC50 value of less than 40 μM; (2) a maximum % Fold (MAX % Fold) value of greater than 75%; and/or (3) a % Fold value at 1.54 μM compound concentration (% Fold@1.54 μM) of at least 75%. In some embodiments, the PKR Activating Compound has: (1) an AC50 value of less than 0.1 μM, 0.1-1.0 μM, or 1.01-40 μM; (2) a MAX % Fold of 75%-250%, 251-500%, or 75%-500%; and/or (3) a % Fold@1.54 μM of 75%-250%, 251-500%, or 75%-500%. In some embodiments, a PKR Activating Compound has (1) an AC50 value of less than 1.0 μM; (2) a MAX % Fold of 75%-500%; and/or (3) a % Fold@1.54 μM of 75%-500%. In some embodiments, the Luminescence Assay Protocol of Example 24 is performed with wild type (wt) PKR, G332S mutant form of PKR or R510Q mutant form of PKR. In some embodiments, a PKR Activating Compound is a compound of Formula I, II, III, or IV.
One aspect of this invention relates to compounds of Formula I:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula I-a:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula I-b:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula I-c:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula I-d-1:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula I-d-2:
or a pharmaceutically acceptable salt thereof,
In some embodiments, a compound of Formula I-a is provided wherein:
In some embodiments, a compound of Formula I-a is provided wherein:
wherein the ring is optionally substituted with (Rd)m;
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, A is a phenyl or monocyclic 5- to 6-membered heteroaryl ring containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, optionally substituted with one or more Ra. In some embodiments, A is phenyl optionally substituted with one or more Ra. In some embodiments, A is monocyclic 5- to 6-membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S (e.g., pyridyl, thiophenyl, imidazolyl, isoxazolyl, or pyrazolyl), optionally substituted with one or more Ra. In some embodiments, A is phenyl, pyridyl, or thiophenyl, each optionally substituted with one or more Ra. In some embodiments, A is phenyl or pyridyl, each optionally substituted with one or more Ra. In some embodiments, A is pyridyl. In some embodiments, A is unsubstituted.
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, each Ra is independently selected from the group consisting of halogen (e.g., fluoro or chloro), —OR (e.g., —OMe, —OiPr, —OCF3, or —OCF2H), —NRC(O)R′ (e.g., —NHC(O)Me), —CN, —S(O)2NR2 (e.g., —SO2NH2), and —C1-C6alkyl (e.g., methyl or —CF3), wherein each alkyl is optionally substituted with one or more halogen. In some embodiments, each Ra is independently selected from the group consisting of halogen (e.g., fluoro or chloro), —OR (e.g., —OMe, —OiPr, or —OCF2H), —CN, —C1-C6alkyl (e.g., methyl or —CF3). In some embodiments, each Ra is independently selected from the group consisting of halogen (e.g., fluoro), —C1-C6alkyl (e.g., methyl), and —OR (e.g., —OMe or —OCF2H).
In some embodiments of Formula I, Z is O or S. In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, Z is NR (e.g., NH2, NOH, or NNH2).
In some embodiments of Formula I, I-a, I-b, I-d-1, and I-d-2, R1 and R2 are each independently selected from the group consisting of —H, halogen, —C1-C6alkyl, —OR, —OC(O)R′, —OS(O)2R′, —OS(O)2NR2, —OC(O)NR2, —OC(O)OR, —(CRbRc)nNR2, —(CRbRc)nNRC(O)R′, —(CRbRc)nNRS(O)2R′, —(CRbRc)nNRC(O)NR2, and —(CRbRc)nNRC(O)OR. In some embodiments, R1 and R2 are each independently selected from the group consisting of —H, halogen (e.g., fluoro), —C1-C6alkyl (e.g., methyl, ethyl, or isopropyl), and —OR (e.g., —OH). In some embodiments, R1 and R2 are each independently selected from the group consisting of —H, halogen (e.g., fluoro), and —OR (e.g., —OH). In some embodiments, one of R1 and R2 is —H. In some embodiments, R1 is —OH and R2 is —H.
In some embodiments of Formula I and I-a, R1 and R2 combine with the carbon to which they are attached to form oxo, a C3-C12cycloalkyl, or 3- to 8-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the heterocyclyl does not contain an O in the γ-position relative to C(═Z), and wherein each cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —C1-C6alkyl, oxo, and —OR, wherein —OR does not result in an O in the γ-position relative to C(═Z). In some embodiments of Formula I and I-a, R1 and R2 combine with the carbon to which they are attached to form a C3-C6cycloalkyl or 3- to 6-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein the heterocyclyl does not contain an O in the γ-position relative to C(═Z), and wherein each cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —C1-C6alkyl, oxo, and —OR, wherein —OR does not result in an O in the γ-position relative to C(═Z).
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, Rb and Rc are each —H. In some embodiments, Rb and Rc are each independently —H or halogen (e.g., fluoro). In some embodiments, Rb and Rc are each independently —H or —C1-C6alkyl (e.g., methyl).
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, each n is independently 0, 1, or 2. In some embodiments, each n is 0 or 1. In some embodiments, each n is 0. In some embodiments, each n is 1. In some embodiments, each n is 2.
In some embodiments of Formula I, I-a, I-b, I-d-1, and I-d-2, B is:
In some embodiments of Formula I, I-a, I-b, I-d-1, and I-d-2, B is an aromatic monocyclic ring or a bicyclic ring wherein at least one of the rings is aromatic, and wherein the monocyclic ring or bicyclic ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the monocyclic ring or bicyclic ring is optionally substituted with (Rd)m. In some embodiments, B is phenyl optionally substituted with (Rd)m. In some embodiments, B is unsubstituted phenyl. In some embodiments, B is phenyl fused to a saturated or partially saturated 5- to 8-membered heterocyclic ring. In some embodiments, B is a monocyclic or bicyclic heteroaryl ring, wherein the ring contains 1-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the ring is optionally substituted with (Rd)m.
In some embodiments of Formula I, I-a, I-b, I-d-1, and I-d-2, B is a monocyclic or bicyclic 3- to 10-membered ring,
In some embodiments of Formula I, I-a, I-b, I-d-1, and I-d-2, B is a monocyclic or bicyclic 3- to 10-membered ring selected from the group consisting of:
wherein the ring is optionally substituted with (Rd)m.
In some embodiments of Formula I, I-a, I-b, I-d-1, and I-d-2, B is a monocyclic or bicyclic 3- to 10-membered ring selected from the group consisting of:
wherein the ring is optionally substituted with (Rd)m.
In some embodiments of Formula I, I-a, I-b, I-d-1, and I-d-2, B is a monocyclic or bicyclic 3- to 10-membered ring selected from the group consisting of:
wherein the ring is optionally substituted with (Rd)m.
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, each Rd is independently selected from the group consisting of halogen, —C1-C6alkyl, —C3-C12cycloalkyl, heterocyclyl, —OR, and —NR2, wherein each alkyl, cycloalkyl, or heterocyclyl are optionally substituted with one or more halogen. In some embodiments, each Rd is independently selected from the group consisting of halogen (e.g., fluoro or chloro), —C1-C6alkyl (e.g., methyl or —CF3), and —OR (e.g., —OMe), wherein each alkyl is optionally substituted with one or more halogen. In some embodiments, each Rd is independently selected from the group consisting of halogen (e.g., fluoro), —C1-C6alkyl (e.g., methyl), and —OR (e.g., —OMe).
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, m is 0, 1, 2, 3, 4, or 5. In some embodiments, m is 0, 1, 2, or 3. In some embodiments, m is 0, 1, or 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2.
In some embodiments of Formula I, R3, R4, R5, R6, R7, R8, R9, and R10 are each —H. In some embodiments, one of R3, R4, R5, R6, R7, R8, R9, and R10 is —C1-C6alkyl (e.g., methyl) and the others are —H.
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, each R is independently selected from the group consisting of —H, —C1-C6alkyl, —C3-C12cycloalkyl, and 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more halogen. In some embodiments, each R is independently selected from the group consisting of —H and —C1-C6alkyl (e.g., methyl or isopropyl), wherein each alkyl is optionally substituted with one or more halogen (e.g., fluoro).
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, each R′ is independently —C1-C6alkyl, —C3-C12cycloalkyl, or 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more halogen. In some embodiments, each R′ is —C1-C6alkyl (e.g., methyl).
In some embodiments of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, the compound is other than:
For example, some embodiments provide a compound of any one or more of Formula I, I-a, I-b, I-c, I-d-1, and I-d-2, other than the compound of the formula:
Another aspect of this invention relates to compounds of Formula II:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula II-a:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula II-b-1:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula II-b-2:
or a pharmaceutically acceptable salt thereof,
In some embodiments, a compound of Formula II-a is provided wherein:
In some embodiments, a compound of Formula II-a is provided wherein:
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, A is:
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, A is an aromatic monocyclic ring or a bicyclic ring wherein at least one of the rings is aromatic, and wherein the monocyclic ring or bicyclic ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the monocyclic ring or bicyclic ring is optionally substituted with one or more Ra.
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, A is a monocyclic or bicyclic 3- to 10-membered ring,
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, A is a monocyclic or bicyclic 3- to 10-membered ring selected from:
wherein the ring is optionally substituted with one or more Ra. In some embodiments, A is a bicyclic ring selected from:
wherein the ring is optionally substituted with one or more Ra. In some embodiments, A is unsubstituted.
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, each Ra is independently selected from the group consisting of halogen, —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, —OR, and —NR2, wherein each alkyl, cycloalkyl, or heterocyclyl are optionally substituted with one or more halogen. In some embodiments of Formula II and II-a, each Ra is independently selected from the group consisting of —C1-C6alkyl (e.g., methyl) and —OR (e.g., —OCHF2).
In some embodiments of Formula II, Z is O or S. In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, Z is NR (e.g., NH2, NOH, or NNH2).
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, R1, R2, and B are each independently —H, halogen, —C1-C6alkyl, —OR, —OC(O)R′, —OS(O)2R′, —OS(O)2NR2, —OC(O)NR2, —OC(O)OR, —(CRbRc)nNR2, —(CRbRc)nNRC(O)R′, —(CRbRc)nNRS(O)2R′, —(CRbRc)nNRC(O)NR2, —(CRbRc)nNRC(O)OR, or —(CRbRc)nC(O)OR,
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, R1, R2, and B are each independently —H, —C1-C6alkyl (e.g., methyl ethyl, propyl, or —CH2CHF2), —OR, —(CRbRc)nNR2 (e.g., —CH2NH2 or —CH2NMe2), —(CRbRc)nNRS(O)2R′ (e.g., —NHS(O)2Me), or —(CRbRc)nC(O)OR (e.g, —CH2C(O)OMe);
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, R1, R2, and B are each independently —H, —C1-C6alkyl (e.g., methyl ethyl, propyl, or —CH2CHF2), —OR, —(CRbRc)nNR2 (e.g., —CH2NH2 or —CH2NMe2), —(CRbRc)nNRS(O)2R′ (e.g., —NHS(O)2Me), or —(CRbRc)nC(O)OR (e.g, —CH2C(O)OMe). In some embodiments, R1 and R2 combine with the carbon to which they are attached to form a C3-C12cycloalkyl (e.g., cyclopropyl, cyclopentyl, or cyclohexyl) or 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of N and S (e.g., pyrrolidinyl, tetrahydrofuranyl, or chromanyl), wherein the heterocyclyl does not contain an O in the γ-position relative to C(═Z), and wherein each cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of —C6aryl, and —C(O)R′.
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, Rb and Rc are each —H. In some embodiments, Rb and Rc are each independently —H or halogen (e.g., fluoro). In some embodiments, Rb and Rc are each independently —H or —C1-C6alkyl (e.g., methyl).
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, each n is independently 0, 1, or 2. In some embodiments, each n is independently 0 or 1. In some embodiments, each n is 0. In some embodiments, each n is 1. In some embodiments, each n is 2.
In some embodiments of Formula II, R3, R4, R5, R6, R7, R8, R9, and R10 are each —H. In some embodiments, one of R3, R4, R5, R6, R7, R8, R9, and R10 is —C1-C6alkyl (e.g., methyl) and the others are —H.
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, each R is independently selected from the group consisting of —H, —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, and C6-C14aryl, wherein each alkyl, cycloalkyl, heterocyclyl or aryl is optionally substituted with one or more halogen or —O(C1-C3alkyl). In some embodiments, each R is independently selected from the group consisting of —H, —C1-C6alkyl (e.g., methyl), and C6-C14aryl (e.g., phenyl, or naphthyl or anthracenyl), wherein each alkyl or aryl is optionally substituted with one or more halogen (e.g., fluoro) or —O(C1-C3alkyl) (e.g., —OMe). In some embodiments, each R is independently —H or methyl. In some embodiments, each R is —H.
In some embodiments of Formula II, II-a, II-b-1, and II-b-2, each R′ is independently selected from the group consisting of —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, —(CRbRc)nC6-C14aryl, or —(CRbRc)nO(C6-C14aryl), wherein each alkyl, cycloalkyl, heterocyclyl, or aryl is optionally substituted with one or more halogen. In some embodiments, each R′ is independently selected from the group consisting of —C1-C6alkyl (e.g., methyl), —(CRbRc)naryl (e.g., phenyl or —CH2phenyl), or —(CRbRc)nO(aryl) (e.g., —CH2O(phenyl)), wherein each methyl or phenyl is optionally substituted with one or more —OMe or —OEt. In some embodiments, each R′ is methyl.
Another aspect of this invention relates to compounds of Formula III:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula III-a:
or a pharmaceutically acceptable salt thereof,
In some embodiments, a compound of Formula III-a is provided wherein:
In some embodiments, a compound of Formula III-a is provided wherein:
In some embodiments of Formula III and III-a, A is:
In some embodiments of Formula III and III-a, A is an aromatic monocyclic ring or a bicyclic ring wherein at least one of the rings is aromatic, and wherein the monocyclic ring or bicyclic ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the monocyclic ring or bicyclic ring is optionally substituted with one or more Ra. In some embodiments, A is a bicyclic ring wherein at least one of the rings is aromatic, and wherein the bicyclic ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the bicyclic ring is optionally substituted with one or more Ra. In some embodiments, A is an aromatic monocyclic ring, wherein the monocyclic ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the monocyclic ring is optionally substituted with one or more Ra. In some embodiments, A is benzofuranyl. In some embodiments, A is unsubstituted.
In some embodiments of Formula III and III-a, each Ra is independently selected from the group consisting of halogen, —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, —OR, and —NR2, wherein each alkyl, cycloalkyl, or heterocyclyl are optionally substituted with one or more halogen.
In some embodiments of Formula III, Z is O or S. In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, Z is NR (e.g., NH2, NOH, or NNH2).
In some embodiments of Formula III and III-a, B is a ring selected from the group consisting of phenyl and 5- to 6-membered heteroaryl (e.g., pyridyl, pyrazinyl, pyrimidinyl, thiazolyl, furanyl, or pyrazolyl) containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein the ring is optionally substituted with one or more Rd. In some embodiments, B is a 5- to 6-membered heteroaryl ring (e.g., pyridyl, pyrazinyl, pyrimidinyl, thiazolyl, furanyl, or pyrazolyl) containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein the ring is optionally substituted with one or more Rd.
In some embodiments of Formula III and III-a, each Rd is independently selected from the group consisting of halogen, —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, —OR, and —NR2, wherein each alkyl, cycloalkyl, or heterocyclyl are optionally substituted with one or more halogen. In some embodiments, each Rd is independently selected from the group consisting of —C1-C6alkyl (e.g., methyl or —CF3), —OR (e.g., —OH, —OCH2CF3), and —NR2 (e.g., —NH(pyridyl)), wherein each alkyl is optionally substituted with one or more halogen (e.g., fluoro).
In some embodiments of Formula III, R3, R4, R5, R6, R7, R8, R9, and R10 are each —H. In some embodiments, one of R3, R4, R5, R6, R7, R8, R9, and R10 is —C1-C6alkyl (e.g., methyl) and the others are —H.
In some embodiments of Formula III and III-a, each R is independently selected from the group consisting of —H, —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, C6-C14aryl (e.g., phenyl, naphthyl, or anthracenyl), and 5- to 14-membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each alkyl, cycloalkyl, heterocyclyl or aryl is optionally substituted with one or more halogen. In some embodiments, each R is independently selected from the group consisting of —H, —C1-C6alkyl, and 5- to 14-membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each alkyl is optionally substituted with one or more halogen. In some embodiments, each R is —H.
In some embodiments of Formula III and III-a, each R′ is independently selected from the group consisting of —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, and C6-C14aryl (e.g., phenyl, naphthyl, or anthracenyl), wherein each alkyl, cycloalkyl, heterocyclyl or aryl is optionally substituted with one or more halogen. In some embodiments, each R′ is —C1-C6alkyl.
Another aspect of this invention relates to compounds of Formula IV:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula IV-a:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula IV-b:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula IV-c:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula IV-d:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula IV-e-1:
or a pharmaceutically acceptable salt thereof,
In some embodiments, compounds are provided that are compounds of Formula IV-e-2:
or a pharmaceutically acceptable salt thereof,
In some embodiments, a compound of Formula IV-a is provided wherein:
In some embodiments, a compound of Formula IV-a is provided wherein:
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, A is:
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, A is an aromatic monocyclic ring or a bicyclic ring wherein at least one of the rings is aromatic, and wherein the monocyclic ring or bicyclic ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the monocyclic ring or bicyclic ring is optionally substituted with one or more Ra. In some embodiments, A is a monocyclic or bicyclic 5- to 10-membered ring, wherein the ring is saturated, fully or partially unsaturated, or aromatic, and wherein the ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S; and wherein the ring is optionally substituted with one or more Ra.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, A is a ring selected from the group consisting of:
wherein the ring is optionally substituted with one or more Ra.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, A is selected from the group consisting of:
wherein the ring is optionally substituted with one or more Ra.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, A is selected from the group consisting of:
wherein the ring is optionally substituted with one or more Ra. In some embodiments, A is unsubstituted.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, each Ra is independently selected from the group consisting of halogen, —OR, and —NR2, —C1-C6alkyl, —C3-C12cycloalkyl, and 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each alkyl, cycloalkyl, or heterocyclyl are optionally substituted with one or more halogen. In some embodiments, each Ra is independently selected from the group consisting of halogen (e.g., fluoro), —C1-C6alkyl (e.g., methyl or —CF3), and —OR (e.g., —OMe or —OCHF2). In some embodiments, each Ra is —OCHF2.
In some embodiments of Formula IV, Z is O or S. In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, Z is NR (e.g., NH2, NOH, or NNH2).
In some embodiments of Formula IV, IV-a, IV-b, IV-e-1, and IV-e-2, X is O or NH. In some embodiments, X is O. In some embodiments, X is NRe. In some embodiments, X is NH.
In some embodiments of Formula IV, IV-a, IV-b, IV-e-1, and IV-e-2, Re is —H. In some embodiments, Re is —C1-C6alkyl (e.g., methyl).
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, B is:
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, B is —H; or a monocyclic 3- to 8-membered ring, wherein the ring is saturated or aromatic, and wherein the ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S; and wherein the ring is optionally substituted with one or more Rd. In some embodiments, B is —H; or a monocyclic 3- to 6-membered ring, wherein the ring is saturated or aromatic, and wherein the ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the ring is optionally substituted with one or more Rd. In some embodiments, B is —H. In some embodiments, B is a monocyclic 3- to 6-membered ring, wherein the ring is saturated or aromatic, and wherein the ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S, and wherein the ring is optionally substituted with one or more Rd. In some embodiments, B is unsubstituted.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, B is —H, or a monocyclic 3- to 6-membered ring selected from the group consisting of phenyl, pyridyl, pyrazinyl, furanyl, pyrazolyl, thiophenyl, isoxazolyl, thiazolyl, oxazolyl, triazolyl, oxadiazolyl, cyclopropyl, and tetrahydrofuranyl, wherein the ring is optionally substituted with one or more Rd. In some embodiments, B is —H, or a monocyclic 3- to 6-membered ring selected from the group consisting of phenyl, pyridyl, pyrazinyl, furanyl, pyrazolyl, isoxazolyl, thiazolyl, oxazolyl, and tetrahydrofuranyl, wherein the ring is optionally substituted with one or more Rd. In some embodiments, B is a monocyclic 3- to 6-membered ring selected from the group consisting of phenyl and furanyl, wherein the ring is optionally substituted with one or more Rd.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, each Rd is independently selected from the group consisting of halogen, —OR, —NR2, —C1-C6alkyl, —C3-C12cycloalkyl, and 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each alkyl, cycloalkyl, or heterocyclyl are optionally substituted with one or more halogen. In some embodiments, each Rd is independently selected from the group consisting of halogen (e.g., fluoro), —C1-C6alkyl (e.g., methyl), and —OR (e.g., —OMe or —OiPr).
In some embodiments of Formula IV and IV-a, R1 and R2 are each independently:
In some embodiments of Formula IV and IV-a, R1 and R2 are each independently —H, halogen, —C1-C6alkyl, —(CRbRc)nC3-C12cycloalkyl, —(CRbRc)nheterocyclyl, —(CRbRc)naryl, —(CRbRc)nheteroaryl, or —(CRbRc)nOR, wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, —C1-C6alkyl, —OR, and oxo, wherein each heterocyclyl is 3- to 14-membered and contains 1-4 heteroatoms selected from the group consisting of O, N, and S, and wherein each heteroaryl is 5- to 14-membered and contains 1-4 heteroatoms selected from the group consisting of O, N, and S. In some embodiments, R1 and R2 combine with the carbon to which they are attached to form a C3-C12cycloalkyl or 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of halogen, —C1-C6alkyl, —OR, and oxo. In some embodiments, Re and R1 combine with the nitrogen to which they are attached to form a 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein the heterocyclyl is optionally substituted with one or more halogen, —C1-C6alkyl, oxo, —OR, and —(CRbRc)nC6-C14aryl. In some embodiments, R2 is absent, and R1 and B combine with the carbon to which they are attached to form C6-C14 aryl ring or 5- to 14-membered heteroaryl ring containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein each aryl or heteroaryl is optionally substituted with one or more halogen, —C1-C6alkyl, or —OR.
In some embodiments of Formula IV and IV-a, R1 and R2 are each independently:
In some embodiments of Formula IV and IV-a, R1 and R2 are each independently —H, —C1-C6alkyl (e.g., methyl, ethyl, or isopropyl), —(CRbRc)nC6-C14aryl (e.g., —CH2(phenyl)), or —(CRbRc)nOR (e.g., —CH2OMe or —CH2CH2OMe), wherein each aryl is optionally substituted with one or more halogen (e.g., fluoro). In some embodiments, R1 and R2 are each —H.
In some embodiments of Formula IV, IV-a, IV-e-1, and IV-e-2, Rb and Rc are each —H. In some embodiments, Rb and Rc are each independently —H or halogen (e.g., fluoro). In some embodiments, Rb and Rc are each independently —H or —C1-C6alkyl (e.g., methyl).
In some embodiments of Formula IV, IV-a, IV-e-1, and IV-e-2, each n is independently 0, 1, or 2. In some embodiments, each n is independently 0 or 1. In some embodiments, each n is 0. In some embodiments, each n is 1. In some embodiments, each n is 2.
In some embodiments of Formula IV, R3, R4, R5, R6, R7, R8, R9, and R10 are each —H. In some embodiments, one of R3, R4, R5, R6, R7, R8, R9, and R10 is —C1-C6alkyl (e.g., methyl) and the others are —H.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, each R is independently selected from the group consisting of —H, —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, and C6-C14aryl (e.g., phenyl, naphthyl, or anthracenyl), wherein each alkyl, cycloalkyl, heterocyclyl or aryl is optionally substituted with one or more halogen. In some embodiments, each R is independently selected from the group consisting of —H or —C1-C6alkyl (e.g., methyl, isopropyl, or —CHF2). In some embodiments R is —H.
In some embodiments of Formula IV, IV-a, IV-b, IV-c, IV-d, IV-e-1, and IV-e-2, each R′ is independently selected from the group consisting of —C1-C6alkyl, —C3-C12cycloalkyl, 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, and C6-C14aryl (e.g., phenyl, naphthyl, or anthracenyl), wherein each alkyl, cycloalkyl, heterocyclyl or aryl is optionally substituted with one or more halogen. In some embodiments, each R′ is —C1-C6alkyl.
In some embodiments, compounds are provided in Table 1:
aCompounds 8-2 and 8-3 are enantiomers, but absolute stereochemistry is undetermined (*);
bCompounds 9-4 and 9-5 are enantiomers, but absolute stereochemistry is undetermined (*);
cCompounds 10-1 and 10-2 are enantiomers, but absolute stereochemistry is undetermined (*);
dCompounds 11-1 and 11-2 are enantiomers, but absolute stereochemistry is undetermined (*).
Unless otherwise stated, it will be appreciated that when “one or more” substituents are recited for a particular variable, it includes one, two, three, four, or more substituents as valency permits.
In some embodiments of any Formula disclosed herein, a heterocyclyl at the R1, R2, or B position does not contain an O in the γ-position relative to C(═Z1) or C(═O). In some embodiments of any Formula disclosed herein, a heterocyclyl at the R1, R2, or B position contains 1-4 heteroatoms independently selected from the group consisting of N and S.
Unless otherwise stated, structures depicted herein are also meant to include all stereoisomeric (e.g., enantiomeric or diastereomeric) forms of the structure, as well as all geometric or conformational isomeric forms of the structure; for example, the R and S configurations for each stereocenter. Therefore, single stereochemical isomers, as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the disclosure. For example, in some cases Table 1 shows one or more stereoisomers of a compound, and unless otherwise indicated, represents each stereoisomer alone and/or as a mixture. Unless otherwise stated, all tautomeric forms of the compounds of the disclosure are within the scope of the disclosure.
In some embodiments, a compound of Formula I, II, III, or IV is obtained by a process comprising a purification method of Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2. In some embodiments, the compound is the obtained by a process comprising a purification method Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2 and is the 1st eluting isomer of the purification method. In some embodiments, the compound is the obtained by a process comprising a purification method Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2 and is the 2nd eluting isomer of the purification method. In some embodiments, the compound is the obtained by a process comprising a purification method Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2 and is the 3rd, 4th, 5th, 6th, 7th, or 8th eluting isomer of the purification method.
In some embodiments, a PKR Activating Compound is obtained by a process comprising a purification method of Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2. In some embodiments, the PKR Activating Compound is the obtained by a process comprising a purification method Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2 and is the 1st eluting isomer of the purification method. In some embodiments, the PKR Activating Compound is the obtained by a process comprising a purification method Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2 and is the 2nd eluting isomer of the purification method. In some embodiments, the PKR Activating Compound is the obtained by a process comprising a purification method Examples 8-2, 8-3, 9-4, 9-5, 10-1, 10-2, 11-1, or 11-2 and is the 3rd, 4th, 5th, 6th, 7th or 8th eluting isomer of the purification method.
Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, compounds having the present structure including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this disclosure.
The disclosure also provides compound of Formulas I, II, III, and IV that are useful, for example, as analytical tools and/or control compounds in biological assays.
The compound of Formulas I, II, III, and IV may form salts which are also within the scope of this disclosure. Reference to a compound of Formula I, II, III, or IV herein is understood to include reference to salts thereof, unless otherwise indicated. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977).
The disclosure also includes pharmaceutical compositions comprising one or more compounds as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, pharmaceutical compositions reported herein can be provided in a unit dosage form (e.g., capsule, tablet or the like). In some embodiments, pharmaceutical compositions reported herein can be provided in an oral dosage form. In some embodiments, the pharmaceutical composition is orally administered in any orally acceptable dosage form. In some embodiments, an oral dosage form of a compound of Formula I, II, III, or IV can be a capsule. In some embodiments, an oral dosage form of a compound of Formula I, II, III, or IV is a tablet. In some embodiments, an oral dosage form comprises one or more fillers, disintigrants, lubricants, glidants, anti-adherents and/or anti-statics. In some embodiments, an oral dosage form is prepared via dry blending. In some embodiments, an oral dosage form is a tablet and is prepared via dry granulation. In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula III, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula IV, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
The pharmaceutical compositions provided herewith may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, and tablets (e.g., in unit dosage forms). In some embodiments, a compound disclosed herein is formulated for oral administering to the subject at a dose of about 10 mg to about 1000 mg, e.g., as a capsule or tablet containing about 50 mg-about 100 mg of a compound disclosed herein and pharmaceutically acceptable carriers and/or excipients. Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician. Pharmaceutical compositions of a compound disclosed herein may comprise one or more additional excipients and/or carriers, with a compound disclosed herein (e.g., a compound of Formulae I, II, III and/or IV) present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% by weight of the pharmaceutical composition.
The designations “α”, “β”, “γ”, “δ”, “ε”, etc. are used herein to refer to a position in a molecule relative to a carbonyl group (e.g., C(═Z) or C(═O)), in accordance with standard nomenclature. For example, a carbon in the α-position (or an α-carbon) is a carbon atom in the position adjacent to a carbonyl group; and an oxygen in the β-position (or a β-oxygen) is an oxygen atom in the position two atoms away from a carbonyl group. The scheme below illustrates this nomenclature on an exemplary compound:
Methods of Using the Disclosed Compounds
Another aspect of the present disclosure is the use of compounds of Formula I, II, III, and IV. Compounds of Formula I, II, III, and IV are useful in medicine. For example, compounds and compositions described herein are activators of PKR. Methods of treatment (e.g., by activating PKR and/or PKM2) can comprise administering to a subject in need thereof a therapeutically effective amount of (i) a compound disclosed herein, or a pharmaceutically acceptable salt thereof or (ii) a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, a method of treating a disease associated with modulation of PKR comprises administering a therapeutically effective amount of a compound disclosed herein. In some embodiments, a method of treating pyruvate kinase deficiency (PKD) comprises administering a therapeutically effective amount of a compound disclosed herein. In some embodiments, a method of treating PKD-associated hemolytic anemia comprises administering a therapeutically effective amount of a compound disclosed herein.
A method of treatment can comprise administering an amount of a compound disclosed herein (e.g., a compound of Formulae I, II, III and/or IV) sufficient to provide a blood concentration of 2,3-DPG that is reduced by at least 15% relative to the reference standard (e.g., from about 15% to about 60%). In some embodiments, the blood concentration of 2,3-DPG is reduced by at least about 15%, by at least about 20%, by at least about 25%, by at least about 30%, by at least about 35%, by at least about 40%, by at least about 45%, by at least about 50%, by at least about 55%, by at least about 60%. In some embodiments, the analysis is performed by sample analysis of bodily fluid, such as blood, by e.g., mass spectroscopy, e.g. LC-MS.
Compounds and compositions described herein are useful as activators of PKR mutants having lower activities compared to the wild type. Such mutations in PKR can affect enzyme activity (catalytic efficiency), regulatory properties (modulation by fructose bisphosphate (FBP)/ATP), and/or thermostability of the enzyme. Examples of such mutations include G332S, G364D, T384M, G37E, R479H, R479K, R486W, R532W, R510Q, and R490W. The activating activity of the present compounds against PKR mutants may be tested following a method described in Example 24. Compounds described herein are also activators of wild type PKR.
A method of treating a patient suffering from or susceptible to a disease or disorder associated with reduced PKM2 activity or reduced glycolysis can include administering a therapeutically effective amount of a compound disclosed herein to a patient in need thereof. The method can include the step of administering an effective amount of a compound described herein to the patient in need thereof, thereby treating, preventing or ameliorating the disease or disorder in the patient. In certain embodiment the compound described herein is provided in a pharmaceutical composition. In certain embodiments, the method includes the step of identifying or selecting a patient who would benefit from activation of PKM2 prior to treatment. Identifying or selecting such a patient can be on the basis of the level of PKM2 activity in a cell of the patient. The compound can be a compound described herein administered at a dosage and frequency sufficient to increase lactate production or oxidative phosphorylation. A method for treating diseases or conditions that are associated with increased 2,3-diphosphoglycerate levels can include administering to a subject in need thereof a therapeutically effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt, solvate or hydrate thereof, (2) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable carrier.
The compounds disclosed herein can be added directly to whole blood or packed cells extracorporeally or be provided to the subject (e.g., the patient). Without being bound by theory, a decrease in the level of 2, 3-DPG concentration induces a leftward shift of the oxygen-hemoglobin dissociation curve and shifts the allosteric equilibrium to the R, or oxygenated state, thus producing a therapeutic inhibition of the intracellular polymerization that underlies sickling by increasing oxygen affinity due to the 2,3-DPG depletion, thereby stabilizing the more soluble oxy-hemoglobin. In another embodiment, to regulate 2,3-diphosphoglycerate, a compound, composition or pharmaceutical composition described herein is added directly to whole blood or packed cells extracorporeally or be provided to the subject (e.g., the patient).
A method of increasing the level of PKM2 activity and/or glycolysis in a patient can include the administration of a therapeutically effective amount of a compound disclosed herein to a patient in need thereof. The method can comprise the step of administering an effective amount of a compound described herein to the patient in need thereof, thereby increasing the level of PKM2 activity and/or glycolysis in the patient. In some embodiments, a compound or a composition described herein is used to maintain PKM2 in its active conformation or activate pyruvate kinase activity in proliferating cells as a means to divert glucose metabolites into catabolic rather than anabolic processes in the patient.
A compound disclosed herein (e.g., a compound of Formulae I, II, III, and/or IV) can activate wild type PKR and/or mutant PKRs. Some examples of the mutant PKRs include G332S, G364D, T384M, G37E, R479H, R479K, R486W, R532W, R510Q, 190N, and R490W. Accordingly, a patient and/or subject can be selected for treatment using a compound of Formulae I, II, III, and/or IV by first evaluating the patient and/or subject to determine whether the subject carries a mutation in PKR (for examples, one of the mutations as described herein), and if the subject is determined to be carrying a mutation in PKR thus is in need of activation of the activity of the mutant PKR, then administering to the subject a therapeutically effective amount of a compound of Formulae I, II, III, and/or IV. A subject can be evaluated as carrying a mutation in PKR using methods known in the art. The subject can also be monitored, for example, subsequent to administration of a compound of Formulae I, II, III, and/or IV. A patient can be monitored for evaluation of certain PK/PD parameters of a compound of Formulae I, II, III, and/or IV such as levels of such compound, levels of 2,3-DPG, or levels of ATP.
In one aspect, the present invention provides a method of treating a subject, the method comprising: administering to the subject a compound of a compound of Formulae I, II, III, and/or IV; and acquiring a value for the level of a compound of Formulae I, II, III, and/or IV, the level of 2,3-diphosphoglycerate (2,3-DPG), the level of adenosine triphosphate (ATP), or the activity of PKR in the subject, to thereby evaluate the subject. The value for the level of a compound of Formulae I, II, III, and/or IV can be acquired by analyzing the plasma concentration of a compound of Formulae I, II, III, and/or IV. In some embodiments, the level of 2,3-DPG is acquired by analyzing the blood concentration of 2,3-DPG. The level of ATP can be acquired by analyzing the blood concentration of ATP. The activity of PKR can be acquired by analyzing the blood concentration of a 13C-label in the blood. For example, 13C-labeled glucose is administered to a subject, and incorporated into certain glycolytic intermediates in the blood.
A method of treatment can comprise administering an amount of a compound disclosed herein (e.g., a compound of Formulae I, II, III and/or IV) sufficient to provide a blood concentration of 2,3-DPG that is reduced by at least 15% relative to the reference standard (e.g; from about 15% to about 60%). In some embodiments, the blood concentration of 2,3-DPG is reduced by at least about 15%, by at least about 20%, by at least about 25%, by at least about 30%, by at least about 35%, by at least about 40%, by at least about 45%, by at least about 50%, by at least about 55%, by at least about 60%. In some embodiments, the analysis is performed by sample analysis of bodily fluid, such as blood, by e.g., mass spectroscopy, e.g. LC-MS.
The compounds described herein can activate mutant PKRs. Accordingly, a patient and/or subject can be selected for treatment using a compound described herein by first evaluating the patient and/or subject to determine whether the subject carries a mutation in PKR, and if the subject is determined to be carrying a mutation in PKR thus is in need of activation of the activity of the mutant PKR, then optionally administering to the subject a compound described herein. A subject can be evaluated as carrying a mutation in PKR using methods known in the art.
Methods of Synthesizing the Disclosed Compounds
The compounds of the present disclosure may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the schemes given below.
The following are illustrative, but non-limiting, examples of certain embodiments of the present disclosure. The synthetic schemes are presented for the synthesis of certain compounds herein disclosed. Definitions used in the following Schemes and elsewhere herein are:
Unless otherwise noted, all materials were obtained from commercial suppliers and were used without further purification. Anhydrous solvents were obtained from Sigma-Aldrich (Milwaukee, WI) and used directly. All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen atmosphere.
LCMS Method 1. Instruments: MS, Waters QDa Mass Detector; HPLC, Waters Acquity Binary Solvent Manager; UV, Waters Acquity PDA. Conditions: Mobile phase A, 95% water/5% acetonitrile with 0.1% formic acid; Mobile phase B, 95% acetonitrile/5% water with 0.09% formic acid. Column: Acquity UPLC BEH C18, 1.7 μm 2.1×50 mm. Column temperature, 35 QC. LC gradient: 5-100% B in 2.0 min, hold 100% to 2.2 min. LC Flow rate, 0.6 mL/min. UV wavelength, 220 nm and 254 nm, Ionization Mode: electrospray Ionization; pos/neg.
To a solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (0.7 g, 3.33 mmol) in acetonitrile (20 mL) and DIEA (1.70 mL, 9.76 mmol) was added benzofuran-5-sulfonyl chloride (17.48 ml, 3.50 mmol) in 1,4 dioxane (17 mL). The resulting mixture was stirred at RT overnight. The reaction mixture was worked up with saturated ammonium chloride solution and EtOAc. The combined organics were washed with brine, dried over Na2SO4, filtered off and concentrated under reduced pressure to give tert-butyl 5-(benzofuran-5-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (1.3 g, 3.33 mmol, 100%) as an oil. LCMS: m/z=413 [M+Na]+.
Tert-butyl 5-(benzofuran-5-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (1.3 g, 3.33 mmol) was dissolved in a mixture of 1,4-dioxane (0.500 mL), DCE (0.25 mL) and 4 M HCl in 1,4-dioxane (0.125 mL) and the reaction was heated at 50° C. for 2 h. The solvents were evaporated under reduced pressure and the reaction mixture was azeotropically dried with toluene and dried further under vacuum overnight to give 2-(benzofuran-5-ylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole hydrochloride (0.95 mg, 3.33 mmol, 100%). LCMS: m/z=291 [M+H]+.
Prepared as described for Intermediate 1, using the appropriate synthetic precursors. 94% overall yield LCMS: m/z=350 [M+H]+.
A mixture of 4-fluorobenzene-1-sulfonyl chloride (2.366 g, 12.16 mmol), tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (2.5 g, 10.13 mmol) and triethylamine (4.24 mL, 30.4 mmol) in DCM (50 mL) was stirred at RT overnight. The solvent was removed under reduced pressure and the residue was taken up in EtOAc, washed with water twice, and dried over sodium sulfate. The crude material was purified on column chromatography on silica gel to afford tert-butyl 5-(4-fluorophenylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (2.5 g, 6.79 mmol, 67%). 1H NMR (300 MHz, CDCl3) δ ppm 7.73-7.92 (m, 2H), 7.14-7.32 (m, 2H), 3.93-4.19 (m, 8H), 1.40 (s, 9H).
A solution of tert-butyl 5-(4-fluorophenylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (2.5 g, 6.79 mmol) in DCM/TFA (1:1, 80 mL) was stirred at RT for 3 days. The volatiles were removed under reduced pressure, the residue was treated with ether, filtered and dried under reduced pressure to give 2-(4-fluorophenylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole, TFA salt (2.48 g, 6.54 mmol, 96%). 1H NMR (300 MHz, DMSO-d6) δ ppm 9.57 (br s, 1H), 7.82-8.06 (m, 2H), 7.32-7.52 (m, 2H), 3.69-4.27 (m, 8H).
Prepared as described for Intermediate 3, using the appropriate synthetic precursors.
Isolated as an orange solid (100 mg). The material was used without further purification. LCMS: m/z=352 [M+H]+.
Isolated as a white solid (90 mg, 87%). LCMS: m/z=252 [M+H]+.
Prepared as described for Intermediate 3, using the appropriate synthetic precursors.
Isolated as a light yellow solid (25 mg, 25%).
Isolated as a brown oil (21 mg, 81%).
To a 50 mL round-bottomed flask was added tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (0.5 g, 2.026 mmol), DIEA (1.059 ml, 6.08 mmol), and dioxane (10 mL) to give a brown suspension. Benzo[d]thiazole-6-sulfonyl chloride (0.497 g, 2.128 mmol) was added. The reaction was heated at 50° C. with stirring for 2 hours. The volatiles were removed under reduced pressure. The residue was resuspended in dioxane (10 mL) and 4 M HCl in dioxane (5.07 ml, 20.26 mmol) was added. The reaction was heated at 50° C. with stirring for 2 hours. The volatiles were removed under reduced pressure to give 6-((3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)benzo[d]thiazole hydrochloride (0.640 g, 1.865 mmol, 92%) as a brown oil that was used in the next step without further purification. LCMS: m/z=307.9 [M+H]+.
Prepared according to the procedure for Intermediate 6, using the appropriate synthetic precursors. Obtained (0.652 g, 1.848 mmol, 91%). LCMS: m/z=317.1 [M+H]+.
To a 50-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was added a solution of tert-butyl 6-bromo-3,4-dihydro-2H-1,4-benzoxazine-4-carboxylate (628 mg, 2.00 mmol, 1.00 equiv) in tetrahydrofuran (20 mL). The mixture was stirred at −78° C. and a solution of (2-methylpropyl)lithium (1.3 M in hexanes, 1.7 mL, 1.10 equiv) in tetrahydrofuran (10 mL) was added dropwise. The reaction mixture was stirred for 15 min at −78° C., then a solution of DMF (292 mg, 4.00 mmol, 2.00 equiv) in THF was added dropwise at −78° C. The reaction mixture was then stirred for 2 h at RT. Water (1 mL) was added, then the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (20 mL), washed with saturated aqueous sodium chloride solution (3×5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified on a silica gel TLC plate eluted with ethyl acetate/petroleum ether (1:3) to provide tert-butyl 6-formyl-3,4-dihydro-2H-1,4-benzoxazine-4-carboxylate (0.3 g, 57%) as a yellow solid. LCMS: m/z=305 [M+1+CH3CN]+.
A solution of tert-butyl 6-formyl-3,4-dihydro-2H-1,4-benzoxazine-4-carboxylate (1 g, 3.80 mmol) in dichloromethane (20 mL) was stirred at 0° C. in a 50-mL round-bottom flask. Trimethylsilanecarbonitrile (1.2 g, 12.10 mmol) was added dropwise at 0° C., followed by addition of ZnI2 (120 mg, 0.38 mmol). The reaction solution was stirred for 16 h at RT and then concentrated under reduced pressure. The residue was diluted with ethyl acetate (50 mL), washed with brine (3×15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to provide tert-butyl 6-[cyano(hydroxy)methyl]-3,4-dihydro-2H-1,4-benzoxazine-4-carboxylate (1.16 g) as a light brown oil. The material was used without further purification. LCMS: m/z=291 [M+1]+.
A solution of tert-butyl 6-[cyano(hydroxy)methyl]-3,4-dihydro-2H-1,4-benzoxazine-4-carboxylate (1 g, 3.44 mmol, 1.00 equiv) in methanol (10 mL) in a 25 mL round-bottom flask was treated dropwise with a saturated solution of HCl in ethyl acetate (15 mL). The reaction mixture was stirred for 1 h at 50° C. The volatiles were removed under reduced pressure and the residue was diluted with water (5 mL). The pH was adjusted to 8 with saturated aqueous sodium carbonate solution. The aqueous phase was extracted with ethyl acetate (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether (1:1) to provide methyl 2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-hydroxyacetate (320 mg, 42%) as a light brown oil. LCMS: m/z=265 [M+1+CH3CN]+.
A mixture of methyl 2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-hydroxyacetate (240 mg, 1.08 mmol, 1.00 equiv), dichloromethane (3 mL), di-tert-butyl dicarbonate (281 mg, 1.29 mmol, 1.20 equiv), TEA (217 mg, 2.14 mmol, 2.00 equiv) and DMAP (13 mg, 0.11 mmol, 0.10 equiv) was stirred for 2 h at RT in a 25-mL round-bottom flask. The volatiles were removed under reduced pressure and the residue was diluted with ethyl acetate (30 mL), washed with brine (3×5 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was applied onto a silica gel column and eluted with CH3CN:H2O (1:4) to provide tert-butyl 6-(1-hydroxy-2-methoxy-2-oxoethyl)-3,4-dihydro-2H-1,4-benzoxazine-4-carboxylate (210 mg, 60%) as a brown oil. LCMS: m/z=365 [M+1+CH3CN]+.
A mixture of tert-butyl 6-(1-hydroxy-2-methoxy-2-oxoethyl)-3,4-dihydro-2H-1,4-benzoxazine-4-carboxylate (110 mg, 0.34 mmol, 1.00 equiv), methanol (1.6 mL), water (0.4 mL) and sodium hydroxide (27 mg, 0.68 mmol, 2.00 equiv) in an 8-mL vial was stirred for 2 h at RT. The volatiles were removed under reduced pressure. The residue was diluted with water (5 mL) and the pH of the solution was adjusted to 4 with concentrated aqueous HCl solution, then the volatiles were removed under reduced pressure to provide 2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-hydroxyacetic acid (120 mg) as a light brown solid. The material was used without further purification. LCMS: m/z=210 [M+1]+.
A mixture of 1,2,3,4-tetrahydroisoquinoline (1.0 g, 7.51 mmol), dichloromethane (15 mL) and TEA (1.1 g, 10.87 mmol) in a 50-mL 3-necked round-bottom flask was stirred for 10 min at 0° C. TFAA (1.9 g, 9.05 mmol) was added. The solution was stirred for 10 min at 0° C. then an additional 2 h at RT. The reaction mixture was concentrated under vacuum. The residue was purified by flash chromatography on silica gel and was eluted with ethyl acetate/petroleum ether (1:10) to provide 2,2,2-trifluoro-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethan-1-one (1.49 g, 87%) as a yellow liquid. LCMS: m/z=271 [M+CH3CN+H]+.
To a 50-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was added dichloromethane (30 mL) and AlCl3 (7.0 g, 52.6 mmol). The reaction mixture was stirred for 10 min at 0° C. in a water/ice bath, then 2,2,2-trifluoro-1-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethan-1-one (3.0 g, 13.09 mmol) and ethyl 2-chloro-2-oxoacetate (2.46 g, 18.02 mmol) were added. The reaction mixture was stirred for an additional 2 h at RT. The reaction mixture was cooled to 0° C. in a water/ice bath, then quenched by the addition of 2 N HCl solution (aqueous 5 mL). The solution was extracted with ethyl acetate and the extract was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel and eluted with ethyl acetate/petroleum ether (1:10) to provide ethyl 2-oxo-2-[2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]acetate (4.1 g, 95%) as a yellow oil. LCMS: m/z=330 [M+H]+.
A mixture of ethyl 2-oxo-2-[2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]acetate (1.0 g, 3.04 mmol, 1.00 equiv), tetrahydrofuran (5 mL) and water (2.5 mL) in a 10-mL round-bottom flask was treated with NaBH4 (56.2 g, 1.49 mol, 0.50 equiv). The reaction mixture was stirred for 30 min at RT, then cooled to 0° C. with a water/ice bath. The reaction was quenched by the addition of water (1 mL) and extracted with ethyl acetate (3×30 mL). The combined extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluted with ethyl acetate/petroleum ether (1:5) to provide ethyl 2-hydroxy-2-[2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]acetate (0.93 g, 92%) as a light yellow oil. 1H NMR (300 MHz, CDCl3): δ ppm 7.31-7.14 (m, 3H), 5.13 (d, J=6.0 Hz, 1H), 4.79-4.74 (m, 2H), 4.34-4.06 (m, 2H), 3.90-3.80 (m, 2H), 3.53 (d, J=6.0 Hz, 1H), 2.97-2.92 (m, 2H), 1.26 (t, J=3.0 Hz, 3H).
A solution of ethyl 2-hydroxy-2-[2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]acetate (990 mg, 2.99 mmol, 1.00 equiv) in methanol (4 mL) and water (1 mL) in a 10-mL round-bottom flask was treated with sodium hydroxide (240 mg, 6.00 mmol, 2.00 equiv). The reaction mixture was stirred for 30 min at RT, then di-tert-butyl dicarbonate (1.3 g, 5.96 mmol, 2.00 equiv) was added and the reaction mixture was stirred for an additional 30 min at RT. The pH value of the solution was adjusted to 6 with 2 N aqueous HCl solution. The reaction mixture was extracted with ethyl acetate, and the extract was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane/methanol (5:1) to provide 2-[2-[(tert-butoxy)carbonyl]-1,2,3,4-tetrahydroisoquinolin-7-yl]-2-hydroxyacetic acid (960 mg) as a white solid. The material was used without further purification.
To an 8-mL vial was added tert-Butyl 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (120 mg, 0.57 mmol, 1.00 equiv), DCM (2.00 mL), (2R)-2-hydroxy-2-phenylacetic acid (104 mg, 0.68 mmol, 1.20 equiv), DIEA (221 mg, 1.71 mmol, 3.00 equiv) and HATU (238 mg, 0.63 mmol, 1.10 equiv). The solution was stirred for 3 h at RT, then concentrated under vacuum. The residue was purified by silica gel column chromatography, eluting with ethyl acetate/petroleum ether (1:1) to provide tert-butyl 5-[(2R)-2-hydroxy-2-phenylacetyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (102 mg, 52%) as a light yellow oil. LCMS: m/z=345 [M+1]+.
To an 8-mL vial was added tert-butyl 5-[(2R)-2-hydroxy-2-phenylacetyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (102 mg, 0.30 mmol, 1.00 equiv), DCM (2.00 mL) and TFA (2.00 mL). The solution was stirred for 2 h at RT, then concentrated under vacuum to provide (R)-2-hydroxy-2-phenyl-1-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethan-1-one, TFA salt (139 mg) as a brown oil. The material was used without further purification. LCMS: m/z=245 [M+1]+.
tert-Butyl 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (200 mg, 0.95 mmol, 1.00 equiv), (2R)-2-hydroxy-2-phenylacetic acid (144 mg, 0.95 mmol, 1.00 equiv), HATU (532 mg, 1.40 mmol, 1.50 equiv), DIEA (181 mg, 1.40 mmol, 1.50 equiv) and DMF (5.00 mL) were combined in a 25-mL round-bottom flask. The solution was stirred for 2 h at RT. The reaction was then quenched by the addition of 20 mL of water. The solution was extracted with 3×15 mL of ethyl acetate and washed with 15 mL of brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel column chromatography, eluting with ethyl acetate/petroleum ether (1:2) to provide tert-butyl 5-[(2R)-2-hydroxy-2-phenylacetyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (120 mg, 37%) as a light yellow solid.
To a 25-mL round-bottom flask was added tert-butyl 5-[(2R)-2-hydroxy-2-phenylacetyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (120 mg, 0.35 mmol, 1.00 equiv) and ethyl acetate freshly saturated with hydrogen chloride (15.0 mL). The solution was stirred overnight at RT. The solids were filtered out and dried under vacuum to provide (R)-2-hydroxy-2-phenyl-1-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethan-1-one hydrochloride (85 mg, 87%) as a gray solid.
To a solution of 2-(benzofuran-5-ylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole hydrochloride (1.07 g, 3.27 mmol) in acetonitrile with 10% DIEA (22 mL) was added (methylsulfonyl)glycine (561 mg, 3.66 mmol) in 1,4-dioxane with 5% DIEA (20 mL), followed by HBTU (1.263 g, 3.33 mmol) in acetonitrile (20 mL). The resulting mixture was stirred at RT overnight. Volatiles were evaporated under reduced pressure and the residue was partitioned between EtOAc and 1 N aqueous NaOH solution. The combined organic phases were washed with brine, dried over Na2SO4, filtered, and the volatiles were evaporated under reduced pressure. The residue was purified by prep HPLC to give N-(2-(5-(benzofuran-5-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-oxoethyl)methanesulfonamide.
The Examples in Table 2 below were prepared according to the procedure outlined above for Example 1-1, using the appropriate synthetic precursors.
To a solution of tert-butyl ((1-(5-(benzofuran-5-ylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)cyclopropyl)methyl)carbamate (14.6 mg, 0.03 mmol) in a 3:1 mixture of DCE/MeOH (0.150 mL) was added 4 M HCl (75 μl, 0.300 mmol) in 1,4-dioxane and the reaction was agitated at RT for 2 hours. The reaction was concentrated and the residue partitioned between EtOAc and saturated aqueous NaHCO3. The combined organics were washed with brine and dried over Na2SO4. The crude material was purified by prep HPLC to yield (1-(aminomethyl)cyclopropyl)(5-(benzofuran-5-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methanone. LCMS: m/z=388 [M+H]+.
To a 0.2 M solution of (tetrahydrofuran-2-yl)methanamine (320 μl, 0.064 mmol) in acetonitrile was added di(1H-imidazol-1-yl)methanone (15.57 mg, 0.096 mmol). The mixture was agitated at RT for 2 hours, then a 0.2 M solution of 2-(benzofuran-5-ylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole (330 μl, 0.066 mmol) in CH3CN with 10% DIEA was added and the mixture was agitated at 50° C. overnight. The solvent was evaporated and the residue was dissolved in 500 μL DMSO and purified by prep HPLC to yield 5-(benzofuran-5-ylsulfonyl)-N-((tetrahydrofuran-2-yl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide (12 mg, 0.029 mmol, 44.9% yield). LCMS: m/z=418 [M+H]+.
The Examples in Table 3 below were prepared according to the procedure outlined above for Example 3-1, using the appropriate synthetic precursors.
To a solution of (R)-2-hydroxy-2-phenyl-1-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethan-1-one (113 mg, 0.462 mmol) and DIEA (0.242 mL, 1.385 mmol) in dichloromethane (6 mL) was added pyridine-3-sulfonyl chloride (54.3 mg, 0.462 mmol). The reaction mixture was stirred at room temperature for 4 hours. Dichloromethane was added to the reaction mixture and the organic phase was washed with water, saturated sodium bicarbonate and brine. The organic phase was concentrated and purified silica by flash column chromatography. (2R)-2-hydroxy-2-phenyl-1-[5-(pyridine-3-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]ethan-1-one was isolated. 1H NMR (300 MHz, CDCl3): δ ppm 8.96 (d, J=1.5 Hz, 1H), 8.85 (dd, J1=1.8 Hz, J2=4.8 Hz, 1H), 8.19-8.23 (m, 1H), 7.63-7.67 (m, 1H), 7.29-7.34 (m, 5H), 5.63 (d, J=6.3 Hz 1H), 5.16 (d, J=6.3 Hz, 1H), 3.93-4.09 (m, 8H). LCMS: m/z=386 [M+H]+.
The Example in Table 4 below were prepared according to the procedure outlined above for Example 4-1, using the appropriate synthetic precursors.
1H-NMR
In a 25 mL pear flask was added triphosgene (40.7 mg, 0.137 mmol) in DCM (5 ml) to give a colorless solution. The solution was cooled to −10° C. and a solution of oxazol-5-ylmethanamine (68.5 mg, 0.698 mmoL) and triethylamine (2.57 mmol) in DCM (10 mL) was added dropwise. The mixture was stirred at RT for 1 hour, then a solution of 2-(4-fluorophenylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole (TFA salt; 267 mg, 0.698 mmol) and triethylamine (2.54 mg, 2.52 mmol) in DCM (5 ml) was added. The mixture was stirred at RT for 5 hours. The reaction was diluted with methylene chloride and washed with aqueous NaOH (1 M), water, and brine. The organic phase was separated, dried with anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by prep-HPLC to provide 5-(4-fluorophenylsulfonyl)-N-(oxazol-5-ylmethyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide (8 mg, 0.0204 mmol, 2.92%). 1H NMR (300 MHz, DMSO-d6): δ ppm 8.39 (br d, J=1.76 Hz, 1H), 7.81-8.01 (m, 2H), 7.36-7.53 (m, 2H), 6.93 (brt, J=5.86 Hz, 1H), 6.18-6.26 (m, 1H), 4.32 (br d, J=5.57 Hz, 2H), 3.90-4.12 (m, 8H). LCMS: m/z=393.06 [M+H]+.
Prepared as described for Example 5-1, using the appropriate synthetic precursors. (20 mg, 0.050 mmol, 7%). 1H NMR (300 MHz, DMSO-d6): δ ppm 7.88 (dd, J=8.79, 5.28 Hz, 2H), 7.43 (t, J=8.79 Hz, 2H), 6.87-7.05 (m, 1H), 4.34 (br d, J=5.57 Hz, 2H), 4.04 (m, 4H), 3.85-3.96 (m, 4H), 2.40 (s, 3H). LCMS: m/z=408.10 [M+H]+.
To a 8-mL vial purged and maintained with an inert atmosphere of nitrogen was added a mixture of 6-[1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]-1,3-benzothiazole hydrochloride (69 mg, 0.20 mmol, 1.00 equiv), N,N-dimethylformamide (2 mL) and DIEA (77 mg, 0.60 mmol, 3.00 equiv), followed by the addition of ditrichloromethyl carbonate (30 mg, 0.10 mmol, 0.50 equiv). The solution was stirred for 1.0 h at RT under nitrogen atmosphere. Morpholine was added (52 mg, 0.60 mmol, 3.00 equiv) and the reaction mixture was stirred for 2 h at RT. The crude product (200 mg) was purified by prep-HPLC with the following conditions: Column: SunFire Prep C18 5 um 19*150 mm; mobile phase: water (buffer of 10 mM NH4HCO3 and 0.05% NH3·H2O) and CH3CN with a gradient of 16% to 34% CH3CN in 10 min; detector UV wavelength: 220 nm. This provided (5-(benzo[d]thiazol-6-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(morpholino)methanone (21.6 mg, 26%) as a white solid. 1H NMR (300 MHz, CDCl3, ppm): δ 9.22 (s, 1H), 8.53 (d, J=1.5 Hz, 1H), 8.29 (d, J=7.8 Hz, 1H), 7.98 (dd, J=8.4 Hz, J=1.8 Hz, 1H), 4.17-4.13 (m, 8H), 3.68-3.65 (m, 4H), 3.27-3.23 (m, 4H). LCMS: m/z=421 [M+H]+.
To an 8-mL vial purged and maintained with an inert atmosphere of nitrogen was added oxane-4-carboxylic acid (31 mg, 0.24 mmol, 1.20 equiv), dichloromethane (3 mL), DIEA (77 mg, 0.60 mmol, 3.00 equiv), 1-(6-[1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]-3,4-dihydro-2H-1,4-benzoxazin-4-yl)ethan-1-one hydrochloride (77 mg, 0.20 mmol, 1.00 equiv) and HATU (91 mg, 0.24 mmol, 1.20 equiv). The reaction mixture was stirred for 16 h at RT, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluted with dichloromethane/methanol (100/1) to provide 1-(6-[5-[(oxan-4-yl)carbonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]-3,4-dihydro-2H-1,4-benzoxazin-4-yl)ethan-1-one (90 mg, 98%) as a white solid. LCMS: m/z=462.2 [M+H]+.
To an 8-mL vial was added 1-(6-[5-[(oxan-4-yl)carbonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]-3,4-dihydro-2H-1,4-benzoxazin-4-yl)ethan-1-one (90 mg, 0.20 mmol, 1.00 equiv), methanol (2 mL), water (0.5 mL) and sodium hydroxide (32 mg, 0.80 mmol, 4.00 equiv). The resulting solution was stirred for 6 h at RT. The crude product was purified by prep-HPLC with the following conditions: Column: Waters XBridge RP18 19*150 mm, 5 um; mobile phase: water (it contains 0.05% NH3·H2O) and CH3CN with a gradient of 28% to 33% CH3CN in 5 min; detector UV wavelength: 220 nm. This provided 6-[5-[(Oxan-4-yl)carbonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]-3,4-dihydro-2H-1,4-benzoxazine (32.3 mg, 39%) as a white solid. 1H NMR (300 MHz, CDCl3): δ ppm 7.14-7.11 (m, 2H), 6.87 (d, J=7.8 Hz, 1H), 4.32-4.00 (m, 12H), 3.48-3.42 (m, 4H), 2.56-2.48 (m, 1H), 2.01-1.81 (m, 2H), 1.62-1.58 (m, 2H). LCMS: m/z=420 [M+H]*.
Into a 50-mL round-bottom flask, was placed a mixture of 2-(pyridin-2-yl)acetic acid hydrochloride (48 mg, 0.28 mmol, 1.00 equiv), 2-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole hydrochloride (100 mg, 0.28 mmol, 1.00 equiv), DIEA (155 mg, 1.20 mmol, 4.00 equiv), dichloromethane (5 mL) and HATU (114 mg, 0.30 mmol, 1.00 equiv). The reaction mixture was stirred for 4 h at 25° C. The reaction was then quenched by the addition of 10 mL of water and the aqueous phase was extracted with 3×10 mL of dichloromethane and washed with water and brine. The crude product (80 mg) was purified by Prep-HPLC with the following conditions. Column: SunFire Prep C18 5 μm 19*150 mm; mobile phase: water (contains 0.1% TFA) and CH3CN with a gradient of 43% to 73% CH3CN in 7 min; detector UV wavelength: 220 nm. This resulted in 25.6 mg (21%) of 1-(5-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-2-(pyridin-2-yl)ethan-1-one as a white solid. 1H NMR (300 MHz, DMSO-d6, ppm): δ 8.50-8.51 (d, J=4.2 Hz, 1H), 7.84-7.89 (m, 2H), 7.71-7.76 (t, J=7.5 Hz, 1H), 7.44-7.46 (d, J=8.1 Hz, 1H), 7.23-7.29 (m, 3H), 6.37-6.85 (t, J=72.6 Hz, 1H), 4.40 (br, 2H), 3.97-4.14 (br, 6H), 3.90-3.94 (br, 2H). LC-MS (ESI) m/z: Calculated for C20H19F2N3O4S: 435.11; found: 436 [M+H]+.
The Examples in Table 5 below were prepared according to the procedure outlined above for Example 8-1, using the appropriate synthetic precursors.
1H-NMR
Into a 8-mL vial (1 atm), was placed a mixture of 2-hydroxy-2-(pyridin-3-yl)acetic acid (39.8 mg, 0.26 mmol, 1.30 equiv), N,N-dimethylformamide (1.5 mL), 2-((4-(difluoromethoxy)phenyl)sulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrolehydrochloride (70.6 mg, 0.20 mmol, 1.00 equiv), DIEA (65 mg, 0.50 mmol, 2.50 equiv) and HATU (91 mg, 0.24 mmol, 1.20 equiv). The resulting solution was stirred for 16 h at room temperature. The reaction solution was diluted with 50 mL of ethyl acetate, washed with 4×10 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by prep-TLC. This resulted in 1-(5-[[4-(Difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-2-hydroxy-2-(pyridin-3-yl)ethan-1-one as an off-white solid. 1H NMR (300 MHz, CDCl3): δ ppm 8.66 (d, J=4.8 Hz, 1H), 8.65-7.87 (m, 2H), 7.51-7.48 (m, 1H), 7.48-7.31 (m, 5H), 5.01 (s, 1H), 4.32-4.15 (m, 7H), 3.63 (d, J=12.3 Hz, 1H). LCMS m/z: 452 [M+H]+.
The Examples in Table 6 below were prepared according to the procedure outlined above for Example 9-1, using the appropriate synthetic precursors.
1H-NMR
To a suspension of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate, HCl (1.10 g, 4.46 mmol) in dichloromethane (25 mL) at room temperature was added TEA (1.49 mL, 10.7 mmol) followed by pyridine-2-sulfonyl chloride (0.950 g, 5.35 mmol). The reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure and the residue was taken up in EtOAc (50 mL). The organic mixture was sequentially washed with water (50 mL) and saturated aqueous sodium chloride solution (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (0% EtOAc/hexane for 5 min then 0-75% EtOAc/hexane for 30 min) to afford tert-butyl 5-(pyridin-2-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (0.57 g, 1.622 mmol, 36.4% yield). LCMS (m/z, M+H+) 351.9, 1H-NMR (300 MHz, CDCl3): δ ppm 8.69 (m, 1H), 8.00-7.88 (m, 2H), 7.49 (m, 1H), 4.33 (m, 4H), 4.05 (m, 4H), 1.45 (s, 9H).
To a solution of tert-butyl 5-(pyridin-2-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (0.570 g, 1.62 mmol) in dichloromethane (4.96 ml) was added 4 M HCl/dioxane (17.6 ml). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure then triturated with ether. The white solid was filtered off to give 2-(pyridin-2-ylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole, HCl (0.547 g, 1.90 mmol, quantitative yield) that was used in the next step without further purification. LCMS (m/z, M+H+) 252.0, 1H-NMR (300 MHz, DMSO-d6): δ ppm 9.99 (br m, 2H), 8.75 (m, 1H), 8.13 (m, 1H), 7.97 (m, 1H), 7.71 (m 1H), 4.24 (m, 4H), 3.89 (m, 4H).
To a suspension of 2-(pyridin-2-ylsulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole, HCl (0.547 g, 1.90 mmol) in dichloromethane (12.6 mL) was added (R)-2-hydroxy-2-phenylacetic acid (0.241 g, 1.58 mmol), BOP (0.771 g, 1.74 mmol) and DIEA (0.830 ml, 4.75 mmol). The reaction mixture was stirred at room temperature for 2 hours. Ethyl acetate (50 mL) was added and the organic phase was washed with saturated aqueous sodium hydrogen carbonate solution (50 mL) and saturated aqueous sodium chloride solution (50 mL). The organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography on (gradient of 0-10% MeOH/dichloromethane) to afford (R)-2-hydroxy-2-phenyl-1-(5-(pyridin-2-ylsulfonyl)-5,6-dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)ethanone (0.353 g, 0.916 mmol, 57.8% yield). LCMS (m/z, M+H+) 385.9, 1H-NMR (300 MHz, DMSO-d6): δ ppm 8.69 (m, 1H), 8.07 (m, 1H), 7.91 (m, 1H), 7.68-7.64 (m, 1H), 7.33-7.26 (m, 5H), 5.64 (d, J=6.0 Hz, 1H), 5.14 (d, J=6.3 Hz, 1H), 4.30-3.88 (m, 8H).
1-(5-[[4-(Difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-hydroxyethan-1-one (174 mg, 0.34 mmol, 1.00 equiv), methanol (2 mL), formaldehyde (20.6 mg, 2.00 equiv), NaBH3CN (64.8 mg, 1.03 mmol, 3.00 equiv) and acetic acid (2 mg, 0.03 mmol, 0.10 equiv) were added to a 10-mL round-bottom flask. The solution was stirred for 1 h at RT, then concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluted with dichloromethane/methanol (15:1) to provide racemic 1-(5-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-2-hydroxy-2-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethan-1-one (140 mg, 78%) as a white solid. The enantiomers were separated by Chiral-Prep-HPLC (SHIMADZU LC-20AT) with the following conditions: Column, Lux Cellulose-4; mobile phase solvent A: ethanol, solvent B: methanol; detector UV wavelength: 220 nm. This provided:
Example 10-1 (first eluting enantiomer): (2R)-1-(5-(4-(difluoromethoxy)phenylsulfonyl)-4,5-dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)-2-hydroxy-2-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)ethanone Isolated as a white solid (26.5 mg, 19%). 1H NMR (300 MHz, CDCl3): δ ppm 7.89 (m, 2H), 7.39 (t, 3H), 6.49-6.65 (m, 3H), 5.32 (d, J=6.6 Hz, 1H), 4.98 (d, J=6.3 Hz, 1H), 3.81-4.25 (m, 10H), 3.21 (m, 2H), 2.75 (d, 3H). LCMS: m/z=522 [M+H]+. * Absolute stereochemistry undetermined.
Example 10-2 (second eluting enantiomer): (2S)-1-(5-(4-(difluoromethoxy)phenylsulfonyl)-4,5-dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)-2-hydroxy-2-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)ethanone Isolated as a white solid (22.7 mg, 16%). 1H NMR (300 MHz, CDCl3): δ ppm 7.86 (m, 2H), 7.20 (m, 2H), 6.37-6.85 (m, 4H), 4.89 (s, 1H), 4.02-4.40 (m, 10H), 3.72 (m, 1H), 3.29 (m, 2H), 2.91 (s, 3H). LCMS: m/z=522 [M+H]+. * Absolute stereochemistry undetermined.
2-[2-[(tert-Butoxy)carbonyl]-1,2,3,4-tetrahydroisoquinolin-7-yl]-2-hydroxyacetic acid (184 mg, 0.60 mmol, 1.00 equiv), 2-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole hydrochloride (187 mg, 0.53 mmol, 1.00 equiv), dichloromethane (5 mL), DIEA (205 mg, 1.59 mmol, 3.00 equiv) and HATU (242 mg, 0.64 mmol, 1.20 equiv) were added to a 50-mL round-bottom flask. The mixture was stirred for 30 min at RT, then the volatiles were removed under reduced pressure. The residue was purified by flash column chromatography on silica gel eluted with dichloromethane/methanol (15:1) to provide tert-butyl 7-[2-(5-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-1-hydroxy-2-oxoethyl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (318 mg, 88%) as a yellow solid. LCMS: m/z=606 [M+H]+.
tert-Butyl 7-[2-(5-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-1-hydroxy-2-oxoethyl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (60.5 mg, 0.10 mmol, 1.00 equiv), dichloromethane (3 mL), and trifluoroacetic acid (1 mL) were added to a 10-mL round-bottom flask. The solution was stirred for 3 h at RT. The pH of the solution was adjusted to 8.0 with 2 N aqueous sodium bicarbonate solution. The mixture was extracted with dichloromethane (3×15 mL), and the combined extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluted with dichloromethane/methanol (10:1) to provide racemic 1-(5-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-2-hydroxy-2-(1,2,3,4-tetrahydroisoquinolin-7-yl)ethan-1-one (40 mg, 79%) as a white solid. The enantiomers were separated by Chiral-Prep-HPLC (SHIMADZU LC-20AT) with the following conditions: Column, DAICEL CHIRALPAK IC 20*250 mm 5 um; mobile phase: solvent A: CH3CN (it contains 0.1% DEA), solvent B: IPA with gradient of 20 to 50% solvent B in 30 min; detector UV wavelength: 230 nm. This provided:
Example 11-1: (2S)-1-(5-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-2-hydroxy-2-(1,2,3,4-tetrahydroisoquinolin-7-yl)ethan-1-one Isolated as a white solid (13.7 mg, 27%). 1H NMR (300 MHz, CD3OD): δ ppm 7.89 (m, 2H), 7.35 (d, J=9.0 Hz, 2H), 7.24-6.75 (m, 4H), 5.33 (s, 1H), 4.25-4.09 (m, 7H), 3.98 (d, J=7.5 Hz, 2H), 3.83-3.79 (m, 1H), 3.09 (t, J=6.3 Hz, 2H), 2.86-2.81 (m, 2H). LCMS: m/z=506 [M+H]+. * Absolute stereochemistry undetermined.
Example 11-2: (2R)-1-(5-[[4-(difluoromethoxy)benzene]sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-2-hydroxy-2-(1,2,3,4-tetrahydroisoquinolin-7-yl)ethan-1-one Isolated as a white solid (11.3 mg, 22%). 1H NMR (300 MHz, CD3OD): δ ppm 7.89 (m, 2H), 7.35 (d, J=9.0 Hz, 2H), 7.24-6.75 (m, 4H), 5.15 (s, 1H), 4.25-4.09 (m, 7H), 3.98 (d, J=7.5 Hz, 2H), 3.83-3.78 (m, 1H), 3.09 (t, J=6.3 Hz, 2H), 2.86-2.81 (m, 2H). LCMS: m/z=506 [M+H]+. * Absolute stereochemistry undetermined.
tert-Butyl 4,5-dihydropyrrolo[3,4-c]pyrrole-2(1H,3H,4H)-carboxylate (84 mg, 0.40 mmol, 1.00 equiv), DCM (8.00 mL), DIEA (77.3 mg, 0.60 mmol, 1.50 equiv) and quinoline-8-sulfonyl chloride (100 mg, 0.44 mmol, 1.10 equiv) were combined in a 50-mL round-bottom flask. The solution was stirred for 16 h at 20° C., then concentrated under vacuum. The residue was diluted with ethyl acetate (10 mL), washed with water (3×3 mL), dried over anhydrous sodium sulfate, filtered then concentrated to provide tert-butyl 5-(quinolin-8-ylsulfonyl)-4,5-dihydropyrrolo[3,4-c]pyrrole-2(1H,3H,4H)-carboxylate as a pink solid (140 mg, 87%). LCMS: m/z=402 [M+H]+.
Ethyl acetate (5.60 mL), concentrated aqueous hydrogen chloride (38 mg, 3.00 equiv), and tert-butyl 5-(quinolin-8-ylsulfonyl)-4,5-dihydropyrrolo[3,4-c]pyrrole-2(1H,3H,4H)-carboxylate (140 mg, 0.35 mmol, 1.00 equiv) were combined in a 50-mL round-bottom flask. The solution was stirred for 6 h at 25° C., then the solids were collected by filtration to provide 8-(4,5-dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-ylsulfonyl) quinoline hydrochloride as a pink solid (110 mg, 93%). LCMS: m/z=302 [M+H]+.
8-(4,5-Dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-ylsulfonyl) quinoline hydrochloride (100 mg, 0.30 mmol, 1.00 equiv), THF (25.0 mL), TEA (179 mg, 1.77 mmol, 6.00 equiv) and ditrichloromethyl carbonate (44 mg, 0.15 mmol, 0.50 equiv) were combined in a 50-mL round-bottom flask. The solution was stirred for 2 h at 25° C. then 3-benzylazetidin-3-ol (97 mg, 0.59 mmol, 2.00 equiv) was added. The solution was stirred for an additional 2 h at 25° C., then diluted with ethyl acetate (50 mL), washed with water (3×25 mL), and dried over anhydrous sodium sulfate. The solids were filtered off. The filtrate was concentrated under vacuum. The crude material was purified by Prep-HPLC with the following conditions: Column, SunFire Prep C18 19*150 mm; mobile phase, water (containing 0.1% TFA) and ACN with a gradient of 39% to 44% of ACN in 6 min; detector UV wavelength, 220 nm. This provided (3-benzyl-3-hydroxyazetidin-1-yl)(5-(quinolin-8-ylsulfonyl)-4,5-dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)methanone as a white solid (44 mg, 30%). 1H NMR (300 MHz, CDCl3, ppm): δ 9.05 (d, J=9.6 Hz, 1H), 8.56 (d, J=6.6 Hz, 1H), 8.32 (d, J=8.1 Hz, 1H), 8.07 (d, J=8.1 Hz, 1H), 7.64 (m, 1H), 7.56 (m, 1H), 7.35 (m, 3H), 7.22 (m, 2H), 4.51 (m, 4H), 4.10 (m, 6H), 3.85 (m, 2H), 3.06 (m, 2H). LCMS: m/z=491 [M+H]+.
(R)-2-hydroxy-2-phenyl-1-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethan-1-one hydrochloride (40 mg, 0.14 mmol, 1.00 equiv), TEA (36 mg, 0.36 mmol, 2.50 equiv) and DCM (4.00 mL) were combined and stirred in a 25-mL round-bottom flask. 4-Sulfamoylbenzene-1-sulfonyl chloride (36.4 mg, 0.14 mmol, 1.00 equiv) was added and the solution was stirred for 2 h at RT. The reaction was then quenched by addition of 4 mL of water, extracted with 3×10 mL of DCM, and washed with 10 mL of brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was re-crystallized from methanol to provide (R)-4-((5-(2-hydroxy-2-phenylacetyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)benzenesulfonamide (24 mg, 36%) as a white solid. 1H NMR (300 MHz, DMSO-d6, ppm): δ 8.01 (s, 4H), 7.62 (br. s, 2H), 7.25-7.34 (m, 5H), 5.61-5.64 (d, 1H), 5.14-5.18 (d, 1H), 3.83-4.30 (m, 8H). LCMS: m/z=464 [M+H]+.
To a 8-mL vial was added tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (75 mg, 0.36 mmol, 1.00 equiv), triethylamine (54 mg, 0.53 mmol, 1.50 equiv), 3-acetamido-4-fluorobenzene-1-sulfonyl chloride (90 mg, 0.36 mmol, 1.00 equiv), and DCM (1.00 mL). The solution was stirred for 3 h at RT. The reaction was then quenched by addition of 10 mL of water. The solution was extracted with 3×10 mL of DCM and washed with 10 mL of brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to provide tert-butyl 5-((3-acetamido-4-fluorophenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (100 mg, 66%) as a white solid. LCMS: m/z=426 [M+H]+.
To a 50-mL round-bottom flask was added tert-butyl 5-((3-acetamido-4-fluorophenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (100 mg, 0.24 mmol, 1.00 equiv) and ethyl acetate freshly saturated with hydrogen chloride gas (20 mL). The solution was stirred overnight at RT. The solids were collected by filtration to provide N-(2-fluoro-5-((3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)phenyl)acetamide hydrochloride (65 mg, 76%) as a gray solid. LCMS: m/z=326 [M+H]+.
To an 8-mL vial was added N-(2-fluoro-5-((3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)phenyl)acetamide hydrochloride (60 mg, 0.17 mmol, 1.00 equiv), (2R)-2-hydroxy-2-phenylacetic acid (25 mg, 0.16 mmol, 1.00 equiv), HATU (94 mg, 0.25 mmol, 1.50 equiv) and DIEA (53 mg, 0.41 mmol, 2.50 equiv), and DMF (5.00 mL). The solution was stirred for 2 h at RT. The reaction was then quenched by the addition of 10 mL of water. The solution was extracted with 3×15 mL of ethyl acetate and washed with 15 mL of brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue (50 mg) was purified by Prep-HPLC (waters I) with the following conditions: Column, Xbridge Prep RP18 5 μm 19*150 mm; mobile phase, water (containing 10 mM NH4HCO3+0.05% ammonia) and CH3CN with a gradient of 87% to 92% CH3CN in 7 min; detector UV wavelength, 254 nm. This provided (R)—N-(2-fluoro-5-((5-(2-hydroxy-2-phenylacetyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)sulfonyl)phenyl)acetamide (7 mg, 9%) as a white solid. 1H NMR (300 MHz, DMSO-d6, ppm): δ 10.04 (s, 1H), 8.49-8.52 (d, J=7.5 Hz, 1H), 7.27-7.53 (m, 7H), 5.61-5.63 (d, J=7.5 Hz, 1H), 5.14-5.16 (d, J=7.5 Hz, 1H), 3.89-4.11 (m, 8H), 2.11 (s, 3H). LCMS: m/z=460 [M+H]+.
To a 250-mL round-bottom flask was added 2-chloro-6-methylpyridine (5.00 g, 39.19 mmol, 1.00 equiv), DMSO (80 mL), phenylmethanethiol (5.37 g, 43.24 mmol, 1.10 equiv) and potassium carbonate (10.9 g, 78.87 mmol, 2.00 equiv). The solution was stirred for 3 h at 150° C., then cooled to RT. The solution was diluted with 300 mL of ethyl acetate, washed with 4×50 mL of brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to provide 2-(benzylsulfanyl)-6-methylpyridine (7.60 g) as a light brown oil. The material was used without further purification. LCMS: m/z=216 [M+H]+.
To a 50-mL round-bottom flask was added 2-(benzylsulfanyl)-6-methylpyridine (580 mg, 2.69 mmol, 1.00 equiv), ACN (20.0 mL), water (0.60 mL) and AcOH (1.30 mL). NCS (1.80 g, 13.48 mmol, 5.00 equiv) was added in portions. The solution was stirred for 2 h at RT, then concentrated under vacuum. The residue was diluted with 5 mL of H2O. The pH value of the solution was adjusted to 8 with saturated aqueous sodium bicarbonate solution. The solution was extracted with 80 mL of ethyl acetate. The organic phase was washed with 3×10 mL of brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography, eluting with ethyl acetate/petroleum ether (1:5) to provide 6-methylpyridine-2-sulfonyl chloride (80 mg, 15%) as a viscous yellow oil. LCMS: m/z=192 [M+H]+.
To an 8-mL vial was added 6-methylpyridine-2-sulfonyl chloride (70 mg, 0.37 mmol, 1.00 equiv), DCM (1.50 mL), DIEA (118 mg, 0.91 mmol, 2.50 equiv), and tert-butyl 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (77 mg, 0.37 mmol, 1.00 equiv). The solution was stirred for 0.5 h at RT, then concentrated. The residue was purified by silica gel column chromatography with DCM/EA (2:1) to provide tert-butyl 5-(6-methylpyridine-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (100 mg, 75%) as a white solid. LCMS: m/z=366 [M+H]+.
To an 8-mL vial was added tert-butyl 5-(6-methylpyridine-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (90 mg, 0.25 mmol, 1.00 equiv) and DCM (1.50 mL). The stirred solution was treated dropwise with EA freshly saturated with hydrogen chloride (3.0 mL). The solution was stirred for 1 h at RT. The mixture was concentrated under vacuum to provide 2-methyl-6-[1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]pyridine hydrochloride (110 mg) as a brown oil. The material was used without further purification. LCMS: m/z=266 [M+H]+.
To an 8-mL vial was added 1-fluoro-2-(isocyanatomethyl)benzene (100 mg, 0.66 mmol, 1.00 equiv), DMF (3.00 mL), DIEA (115 mg, 0.89 mmol, 3.00 equiv) and 2-methyl-6-[1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-sulfonyl]pyridine hydrochloride (49 mg, 0.14 mmol, 0.90 equiv). The solution was stirred for 1 h at RT, then concentrated. The residue was purified by Prep-HPLC (Waters I) with the following conditions: Column, Waters XBridge RP18 19*150 mm, 5 μm; mobile phase, water (containing 10 mM NH4HCO3+0.05% ammonia) and ACN with a gradient of 42% to 65% ACN in 7 min; flow rate, 20 mL/min; detector UV wavelength, 254 nm. This provided N-[(2-fluorophenyl)methyl]-5-(6-methylpyridine-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxamide (54 mg, 20%) as a white solid. 1H NMR (300 MHz, CDCl3, ppm): δ 7.83-7.76 (m, 2H), 7.44-7.34 (m, 2H), 7.32-7.23 (m, 1H), 7.14-7.02 (m, 1H), 4.60 (d, J=6.0 Hz, 1H), 4.51 (d, J=5.7 Hz, 2H), 4.37 (s, 4H), 4.12 (s, 4H), 2.61 (s, 3H). LCMS: m/z=417 [M+H]+.
To an 8-mL vial was added 2-(pyridin-3-yl)acetic acid (78.3 mg, 0.57 mmol, 1.20 equiv), DCM (2.00 mL), DIEA (184 mg, 1.42 mmol, 1.00 equiv), tert-butyl 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (100 mg, 0.48 mmol, 1.00 equiv) and HATU (200 mg, 0.53 mmol, 1.10 equiv). The solution was stirred for 2 h at RT, then concentrated under vacuum. The residue was purified by silica gel column chromatography, eluting with DCM/methanol (50:1) to provide tert-butyl 5-[2-(pyridin-4yl)acetyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (135 mg) as a brown oil. The material was used without further purification. LCMS: m/z=330 [M+H]+.
To an 8-mL vial was added tert-butyl 5-[2-(pyridin-4yl)acetyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (135 mg, 0.41 mmol, 1.00 equiv) and DCM (2.00 mL). The stirred solution was treated with ethyl acetate freshly saturated with hydrogen chloride (2.00 mL). The solution was stirred for 2 h at RT, then the solids were collected by filtration to provide 2-(pyridin-3-yl)-1-[1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]ethan-1-one hydrochloride (125 mg) as a light brown solid. The material was used without further purification. LCMS: m/z=230 [M+H]+.
To an 8-mL vial was added 2-(pyridin-3-yl)-1-[1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]ethan-1-one hydrochloride (115 mg, 0.43 mmol, 1.00 equiv), DMF (4 mL), pyridine-2-sulfonyl chloride (84.1 mg, 0.47 mmol, 1.10 equiv) and DIEA (139 mg, 1.08 mmol, 2.50 equiv). The solution was stirred for 2 h at RT. The mixture was purified by Prep-HPLC (Waters 2767) with the following conditions: Column, X-Bridge RP18, 19*150 mm, 5 μm; mobile phase, water (containing 10 mM NH4HCO3+0.05% ammonia) and CH3CN with a gradient of 16% to 36% CH3CN in 8 min; detector UV wavelength, 220 nm. This provided 2-(pyridin-3-yl)-1-[5-(pyridine-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]ethan-1-one (25.5 mg, 16%) as a light yellow solid. 1H NMR (300 MHz, DMSO-d6, ppm): δ 8.75 (d, J=3.9 Hz, 1H), 8.44-8.41 (m, 2H), 8.16-8.10 (m, 1H), 7.97 (d, J=7.8 Hz, 1H), 7.72 (dd, J=4.8 Hz, J=1.5 Hz, 1H), 7.71-7.69 (m, 1H), 7.32 (dd, J=7.2 Hz, J=4.8 Hz, 1H), 4.31-4.26 (m, 6H), 4.03 (s, 2H), 3.68 (s, 2H). LCMS: m/z=371 [M+H]+.
Prepared as described for Step 3 of the preparation of Example 16-1 using the appropriate synthetic precursors, but with a two hour reaction time, and using a Prep-HPLC gradient of 20% to 40% ACN in 8 minutes. Isolated as a white solid (48.3 mg, 29%). 1H NMR (300 MHz, DMSO-d6, ppm): δ 8.19 (d, J=1.5 Hz, 1H), 8.12-8.01 (m, 2H), 7.86-7.83 (m, 1H), 7.59 (s, 2H), 7.34-7.30 (m, 5H), 5.64 (d, J=6.3 Hz, 1H), 5.16 (d, J=6.0 Hz, 1H), 4.25-3.87 (m, 8H). LCMS: m/z=464 [M+H]+.
To a 1.5 mL vial was added a 0.2 M solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (100 μL, 20 μmol) in dioxane and neat DIEA (10 μL, 57 μmol) to give a brown suspension. A 0.2 M solution of 1-methyl-1H-pyrazole-3-sulfonyl chloride (105 μL, 20 μmol) in dioxane was added. The reaction was heated at 50° C. with shaking for 2 hours. 4 M HCl in dioxane (50.0 μL, 0.200 mmol) was then added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. ACN (200 uL) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. Neat DIEA (25 μL, 0.143 mmol) and a 0.2 M solution of 3-methyl-2-phenylbutanoic acid (110 μL, 22 μmol) in dioxane was added to the vial, followed by a 0.2 M solution of HBTU (110 μL, 22 μmol) in ACN. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The volatiles were removed under reduced pressure. The compound was purified using mass-triggered HPLC to give 3-Methyl-1-{5-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}-2-phenylbutan-1-one. LCMS: m/z=415.1 [M+H]+.
The Examples in Table 7 below were prepared according to the procedure outlined above for Example 18-1, using the appropriate synthetic precursors.
A 0.2 M solution of 4-(difluoromethoxy)benzenesulfonyl chloride (158 μL, 31.5 μmol) in dioxane was added to a 1.5 mL vial charged with a 0.2 M solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (150 μL, 30 μmol) in a solvent mixture of acetonitrile/DIEA (90:10). The reaction mixture was heated at 50° C. with shaking for 2 hours. Dioxane (200 μL), methanol (200 μL), and a solution of 4 N HCl in dioxane (100 μL, 0.200 mmol) was added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. ACN (200 uL) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. Neat DIEA (25 μL, 0.143 mmol) and a 0.2 M solution of 2-(1H-tetrazol-1-yl)acetic acid (165 μL, 33 μmol) in dioxane was added to the vial, followed by a 0.2 M solution of HBTU (165 μL, 33 μmol) in ACN. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The organic layer was concentrated under reduced pressure. The compound was purified using mass-triggered HPLC to give 1-(5-((4-(difluoromethoxy)phenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-(1H-tetrazol-1-yl)ethan-1-one (4.9 mg, 38% yield). LCMS: m/z=427.1 [M+H]+, Rt: 1.10 min (LCMS method 1).
A 0.2 M solution of 4-(difluoromethoxy)benzenesulfonyl chloride (158 μL, 31.5 μmol) in dioxane was added to a 1.5 mL vial charged with a 0.2 M solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (150 μL, 30 μmol) in a solvent mixture of acetonitrile/DIEA (90:10). The reaction mixture was heated at 50° C. with shaking for 2 hours. Dioxane (200 μL), methanol (200 μL), and a solution of 4 N HCl in dioxane (100 μL, 0.200 mmol) was added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. ACN (200 uL) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. Neat DIEA (25 μL, 0.143 mmol) and a 0.2 M solution of 2,2-difluoro-2-phenylacetic acid (165 μL, 33 μmol) in dioxane was added to the vial, followed by a 0.2 M solution of HBTU (165 μL, 33 μmol) in ACN. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The organic layer was concentrated under reduced pressure. The compound was purified using mass-triggered HPLC to give 1-(5-((4-(difluoromethoxy)phenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2,2-difluoro-2-phenylethan-1-one (1.7 mg, 12% yield). LCMS: m/z=471.1 [M+H]+, Rt: 1.58 min (LCMS method 1).
To a 1.5 mL vial was added a 0.2 M solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (100 μL, 20 μmol), a 0.2 M solution of (R)-2-phenylpropanoic acid (110 μL, 22 μmol), and neat DIEA (10 μL, 0.057 mmol) to give a brown suspension. A 0.2 M solution of HBTU (110 μL, 22 μmol) in ACN was added. The reaction was shaken for 2 hours at RT. 4 M HCl in dioxane (50.0 μL, 0.200 mmol) was added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were evaporated under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The volatiles were evaporated under reduced pressure and ACN (200 μM) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue, then neat DIEA (10 μL, 57 μmol) was added to the vial followed by a 0.2 M solution of 5-chlorothiophene-2-sulfonyl chloride (110 μL, 22 μmol) in dioxane. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The volatiles were removed under reduced pressure. The compound was purified using mass-triggered HPLC to provide (2R)-1-{5-[(5-chlorothiophen-2-yl)sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}-2-phenylpropan-1-one. LCMS: m/z=423.1 [M+H]+.
The Examples in Table 8 below were prepared according to the procedure outlined above for Example 19-1, using the appropriate synthetic precursors.
A 0.2 M solution of 1,2-dimethyl-1H-imidazole-4-sulfonyl chloride (158 μL, 31.5 μmol) in dioxane was added to a 1.5 mL vial charged with a 0.2 M solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (150 μL, 30 μmol) in a solvent mixture of acetonitrile/DIEA (90:10). The reaction mixture was heated at 50° C. with shaking for 2 hours. Dioxane (200 μL), methanol (200 μL), and a solution of 4 N HCl in dioxane (100 μL, 0.200 mmol) was added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. ACN (200 uL) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. Neat DIEA (25 μL, 0.143 mmol) and a 0.2 M solution of 3-(1H-benzo[d]imidazol-1-yl)-2-oxobutanoic acid (165 μL, 33 μmol) in dioxane was added to the vial, followed by a 0.2 M solution of HBTU (165 μL, 33 μmol) in ACN. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The organic layer was concentrated under reduced pressure. The compound was purified using mass-triggered HPLC to give 2-(1H-benzo[d]imidazol-1-yl)-1-(5-((1,2-dimethyl-1H-imidazol-4-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propan-1-one (7.5 mg, 55% yield). LCMS: m/z=455.2 [M+H]+, Rt: 0.78 min (LCMS method 1).
To a 1.5 mL vial was added a 0.2 M solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (100 μL, 20 μmol) in ACN, a 0.2 M solution of 2-(isocyanatomethyl)furan (110 μL, 22 μmol) in dioxane, and neat DIEA (10 μL, 57 μmol) to give a brown suspension. The reaction was shaken at RT for 2 hours. 4 M HCl in dioxane (50.0 μL, 0.200 mmol) was added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure and ACN (0.2 μL) was added to the vial along with DIEA (25 μL, 0.143 mmol). The vial was shaken for 15 minutes to resuspend the residue, then a 0.2 M solution of pyridine-3-sulfonyl chloride (110 μL, 22 μmol) in dioxane was added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The volatiles were removed under reduced pressure. The compound was purified using mass-triggered HPLC to yield N-(furan-2-ylmethyl)-5-(pyridin-3-ylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide (1.9 mg, 5.08 μmol, 25% yield). LCMS: m/z=375.2 [M+H]+.
The Examples in Table 9 below were prepared according to the procedure outlined above for Example 20-1, using the appropriate synthetic precursors.
To a 1.5 mL vial was added a 0.2 M solution of 6-((5,6-dihydropyrrolo[3,4-c]pyrrol-2(1H,3H,4H)-yl)sulfonyl)benzo[d]thiazole (150 μL, 0.030 mmol) in ACN, a 0.2 M solution of 2-(isocyanatomethyl)furan (150 μL, 0.030 mmol) in ACN, and DIEA (25 μL, 0.144 mmol) to give a brown suspension. The reaction was shaken at RT for 2 hours. The reaction was dried down under a stream of nitrogen. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with EtOAc (2×0.5 mL). The extracts were dried under a stream of nitrogen. The compound was purified using mass-triggered HPLC to yield 5-(benzo[d]thiazol-6-ylsulfonyl)-N-(furan-2-ylmethyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxamide (2.1 mg, 4.88 mol, 16 yield). LCMS: m/z=431.0 [M+H]+.
The Examples in Table 10 below were prepared according to the procedure outlined above for Example 21-1, using the appropriate synthetic precursors.
In a 1.5 mL reaction vial was added a 0.2M solution of 4-nitrophenyl(pyridin-3-ylmethyl)carbonate (180 μL, 0.036 mmol) in ACN, neat DIEA (15 μL, 0.086 mmol) and a 0.2M solution of 2-((4-(difluoromethoxy)phenyl)sulfonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole hydrochloride (150 μL, 0.030 mmol) in ACN containing 5% DIEA to give a brown solution. The reaction was shaken at RT for 2 hours. The volatiles were removed under a stream of nitrogen. The residue was partitioned between 0.5 mL of 1N NaOH and 0.5 mL of EtOAc. The organic layer was removed. The aqueous layer was extracted with 0.5 mL of EtOAc. The organic layers were combined and the volatiles removed under a stream of nitrogen. The residue was purified using mass-triggered HPLC to provide pyridin-3-ylmethyl 5-((4-(difluoromethoxy)phenyl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (5.6 mg, 12.4 μmol, 41% yield). LCMS: m/z=452.2 [M+H]+.
The Examples in Table 11 below were prepared according to the procedure outlined above for Example 22-1, using the appropriate synthetic precursors.
To a 1.5 mL vial was added a 0.2 M solution of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate hydrochloride (150 μL, 30 μmol) in dioxane and neat DIEA (10 μL, 57 μmol) to give a brown suspension. A 0.2 M solution of benzofuran-5-sulfonyl chloride (158 μL, 31.5 μmol) in dioxane was added. The reaction was heated at 50° C. with shaking for 2 hours. 4 M HCl in dioxane (75.0 μL, 0.300 mmol) was then added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. ACN (200 μL) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. Neat DIEA (50 μL, 0.285 mmol) and a 0.2 M solution of (tert-butoxycarbonyl)proline (165 μL, 33 μmol) in dioxane was added to the vial, followed by a 0.2 M solution of HBTU (165 μL, 33 μmol) in ACN. The reaction was shaken at room temperature for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The organic layers were combined and the volatiles were removed under reduced pressure. Dioxane (200 μL) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. 4 M HCl in dioxane (75.0 μL, 0.300 mmol) was then added. The reaction was heated at 50° C. with shaking for an additional 2 hours. The volatiles were removed under reduced pressure. ACN (200 μL) was added to the vial. The vial was shaken for 15 minutes to resuspend the residue. Neat DIEA (50 μL, 0.285 mmol) and a 0.2 M solution of benzoic acid (165 μL, 33 μmol) in dioxane was added to the vial, followed by a 0.2 M solution of HBTU (165 μL, 33 μmol) in ACN. The reaction was shaken at room temperature for an additional 2 hours. The volatiles were removed under reduced pressure. The residue was mixed with 1 N NaOH (0.5 mL) and extracted with 3:1 EtOAc/ACN (2×0.5 mL). The organic layers were combined and the volatiles were removed under reduced pressure. The compound was purified using mass-triggered HPLC to give 2-(benzofuran-5-ylsulfonyl)-5-(benzoylprolyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole (2.0 mg, 6.52 μmol, 22% yield). LCMS: m/z=492.3.1 [M+H]+.
The Examples in Table 12 below were prepared according to the procedure outlined above for Example 23-1, using the appropriate synthetic precursors.
In some embodiments, a PKR Activating Compound refers to a compound having one or more characteristics when tested according to the following Luminescence Assay Protocol of Example 24 performed with wild type (wt) PKR and/or any one or more of G332S mutant form of PKR or R510Q mutant form of PKR: (1) an AC50 value of less than 40 μM (e.g., compounds with AC50 values of “+”, or “+++” in Table 13); (2) a maximum % Fold (MAX % Fold) value of greater than 75%; and/or (3) a % Fold value at 1.54 μM compound concentration (% Fold@1.54 μM) of at least 75%. In some embodiments, a PKR Activating Compound can have: (1) an AC50 value of less than 0.1 μM (e.g., compounds with AC50 values of “+++” in Table 13), 0.1-1.0 μM (e.g., compounds with AC50 values of “++” in Table 13), or 1.01-40 μM (e.g., compounds with AC50 values of “+” in Table 13); (2) a MAX % Fold of 75%-250%, 250-500%, or 75%-500%; and/or (3) a % Fold@1.54 μM of 75%-250%, 250-500%, or 75%-500%. In some embodiments, a PKR Activating Compound has (1) an AC50 value of less than 1.0 μM; (2) a MAX % Fold of 75%-500%; and/or (3) a % Fold@1.54 μM of 75%-500%.
The phosphorylation of Adenosine-5′-diphosphate (ADP) by various mutants of PKR was determined by the Kinase Glo Plus Assay (Promega) in the presence or absence of FBP [D-Fructose-1,6-diphosphate; BOC Sciences, CAS: 81028-91-3] as follows. Unless otherwise indicated, all reagents were purchased from Sigma-Aldrich. All reagents were prepared in buffer containing 50 mM Tris-HCl, 100 mM KCl, 5 mM MgCl2, and 0.01% Triton X100, 0.03% BSA, and 1 mM DTT. Enzyme and PEP [Phospho(enol) pyruvic acid] were added at 2× to all wells of an assay-ready plate containing serial dilutions of test compounds or DMSO vehicle. Final enzyme concentrations for PKR(wt), PKR(R510Q), and PKR(G332S) were 0.8 nM, 0.8 nM, and 10 nM respectively. Final PEP concentration was 100 μM. The Enzyme/PEP mixture was incubated with compounds for 30 minutes at RT before the assay was initiated with the addition of 2×ADP [Adenosine-5′-diphosphate] and KinaseGloPlus. Final concentration of ADP was 100 μM. Final concentration of KinaseGloPlus was 12.5%. For assays containing FBP, that reagent is added at 30 μM upon reaction initiation. Reactions were allowed to progress for 45 minutes at RT until luminescence was recorded by the BMG PHERAstar FS Multilabel Reader. All compounds were tested in triplicate at concentrations ranging from 42.5 μM to 2.2 nM in 0.83% DMSO.
Luminescence values were converted to % Fold increase by normalizing to the average of the DMSO control and multiplying by 100. Max, min, slope and AC50 were determined by the standard four parameter fit algorithm of ActivityBase XE Runner. Compounds were evaluated with three parameters—AC50, MAX % Fold, and % Fold@1.54 μM (
As set forth in Table 13 below, AC50 values (columns A, D, G) are defined as follows: ≤0.1 μM (+++); >0.1 μM and ≤1.0 μM (++); >1.0 μM and ≤40 μM (+); >40 μM (0). Max % FOLD values (columns B, E, H) are defined as follows: ≤75% (+); >75% and ≤250% (++); >250% and ≤500% (+++). % Fold@1.54 μM values (columns C, F, J) are defined as follows: ≤75% (+); >75% and ≤250% (++); >250% and ≤50000 (+++).
1A - AC50 LUM KGP FBP AC50 μM gmean;
1A-AC50 LUM KGP FBP AC50 μM gmean;
The present disclosure enables one of skill in the relevant art to make and use the inventions provided herein in accordance with multiple and varied embodiments. Various alterations, modifications, and improvements of the present disclosure that readily occur to those skilled in the art, including certain alterations, modifications, substitutions, and improvements are also part of this disclosure. Accordingly, the foregoing description and drawings are by way of example to illustrate the discoveries provided herein.
Embodiment 1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Embodiment 2. The compound of embodiment 1, wherein the compound is of Formula I-a:
or a pharmaceutically acceptable salt thereof.
Embodiment 3. The compound of embodiment 2, wherein the compound is of Formula I-b:
or a pharmaceutically acceptable salt thereof.
Embodiment 4. The compound of any one of embodiments 1-3, wherein B is an aromatic monocyclic ring or a bicyclic ring,
Embodiment 5. The compound of any one of embodiments 1-4, wherein R1 and R2 are each independently selected from the group consisting of —H, halogen, —C1-C6alkyl, and —OR, wherein —OR does not result in an O in the γ-position relative to C(═Z).
Embodiment 6. The compound of any one of embodiments 1-3, wherein the compound is of Formula I-c:
or a pharmaceutically acceptable salt thereof.
Embodiment 7. The compound of any one of embodiments 1-5, wherein the compound is of Formula I-d-1:
or a pharmaceutically acceptable salt thereof.
Embodiment 8. The compound of any one of embodiments 1-5, wherein the compound is of Formula I-d-2:
or a pharmaceutically acceptable salt thereof,
Embodiment 9. The compound of any one of embodiments 1-8, wherein A is phenyl or pyridyl, optionally substituted with one or more Ra.
Embodiment 10. The compound of any one of embodiments 1-9, wherein each Ra is selected from the group consisting of halogen, —C1-C6alkyl, and —OR.
Embodiment 11. The compound of any one of embodiments 1-10, wherein A is pyridyl.
Embodiment 12. The compound of any one of embodiments 1-11, wherein each Rd is selected from the group consisting of halogen, —C1-C6alkyl, and —OR.
Embodiment 13. The compound of any one of embodiments 1-12, wherein A is unsubstituted.
Embodiment 14. The compound of any one of embodiments 1-13, wherein each R is independently selected from the group consisting of —H and —C1-C6alkyl.
Embodiment 15. A compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
Embodiment 16. The compound of embodiment 15, wherein the compound is of Formula II-a:
or a pharmaceutically acceptable salt thereof.
Embodiment 17. The compound of embodiment 15 or 16, wherein the compound is of Formula II-b-1:
or a pharmaceutically acceptable salt thereof,
Embodiment 18. The compound of embodiment 15 or 16, wherein the compound is of Formula II-b-2:
or a pharmaceutically acceptable salt thereof,
Embodiment 19. The compound of any one of embodiments 15-18, wherein A is a monocyclic or bicyclic 3- to 10-membered ring,
Embodiment 20. The compound of any one of embodiments 15-19, wherein Ra is selected from the group consisting of halogen, —OR, —NR2, —C1-C6alkyl, —C3-C12cycloalkyl, and 3- to 14-membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S,
Embodiment 21. The compound of any one of embodiments 15-20, wherein:
Embodiment 22. The compound of any one of embodiments 15-21, wherein R1, R2, and B are each independently —H, —C1-C6alkyl, —OR, —(CRbRc)nNR2, —(CRbRc)nNRS(O)2R′, or —(CRbRc)nC(O)OR, wherein each alkyl is optionally substituted with one or more halogen.
Embodiment 23. The compound of any one of embodiments 15-21, wherein:
Embodiment 24. The compound of any one of embodiments 15-23, wherein B is —H.
Embodiment 25. The compound of any one of embodiments 15-24, wherein each R is independently selected from the group consisting of —H, —C1-C6alkyl, and C6-C14aryl.
Embodiment 26. The compound of any one of embodiments 15-25, wherein each R′ is —C1-C6alkyl.
Embodiment 27. A compound of Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
Embodiment 28. The compound of embodiment 27, wherein the compound is of Formula III-a:
or a pharmaceutically acceptable salt thereof.
Embodiment 29. The compound of embodiment 27 or 28, wherein A is a 5- to 10-membered aromatic monocyclic ring or a bicyclic ring,
Embodiment 30. The compound of any one of embodiments 27-29, wherein A is a bicyclic aromatic ring containing 0-4 heteroatoms independently selected from the group consisting of O, N, and S.
Embodiment 31. The compound of any one of embodiments 27-30, wherein B is a ring selected from phenyl or 5- to 6-membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S, wherein the ring is optionally substituted with one or more Rd.
Embodiment 32. The compound of any one of embodiments 27-31, wherein each Rd is independently selected from the group consisting of —OR, —NR2, and —C1-C6alkyl optionally substituted with one or more halogen.
Embodiment 33. The compound of any one of embodiments 27-32, wherein each R is independently selected from the group consisting of —H, —C1-C6alkyl optionally substituted with one or more halogen, and 5- to 14-membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N, and S.
Embodiment 34. A compound of Formula IV:
or a pharmaceutically acceptable salt thereof, wherein: A is a monocyclic or bicyclic 3- to 14-membered ring, wherein the ring is saturated, fully or partially unsaturated, or aromatic, and wherein the ring contains 0-4 heteroatoms independently selected from the group consisting of O, N, and S; and wherein the ring is optionally substituted with one or more Ra;
Embodiment 35. The compound of embodiment 34, wherein the compound is of Formula IV-a:
or a pharmaceutically acceptable salt thereof.
Embodiment 36. The compound of embodiment 34 or 35, wherein the compound is of Formula IV-b:
or a pharmaceutically acceptable salt thereof.
Embodiment 37. The compound of any one of embodiments 34-36, wherein the compound is of Formula IV-c:
or a pharmaceutically acceptable salt thereof.
Embodiment 38. The compound of any one of embodiments 34-36, wherein the compound is of Formula IV-d:
or a pharmaceutically acceptable salt thereof.
Embodiment 39. The compound of any one of embodiments 34-36, wherein the compound is of Formula IV-e-1:
or a pharmaceutically acceptable salt thereof.
Embodiment 40. The compound of any one of embodiments 34-36, wherein the compound is of Formula IV-e-2:
or a pharmaceutically acceptable salt thereof,
Embodiment 41. The compound of any one of embodiments 34-40, wherein A is a 5- to 10-membered aromatic monocyclic ring or a bicyclic ring,
Embodiment 42. The compound of any one of embodiments 34-41, wherein each Ra is independently selected from the group consisting of halogen, —C1-C6alkyl, and —OR.
Embodiment 43. The compound of any one of embodiments 34-42, wherein:
Embodiment 44. The compound of any one of embodiments 34-43, wherein each Rd is independently selected from the group consisting of halogen, —C1-C6alkyl, and —OR.
Embodiment 45. The compound of any one of embodiments 34-44, wherein:
Embodiment 46. The compound of any one of embodiments 34-45, wherein R1 and R2 are each —H.
Embodiment 47. The compound of any one of embodiments 34-46, wherein Rb and Re are each —H, and each n is 0, 1, or 2.
Embodiment 48. The compound of any one of embodiments 34-47, wherein each R is independently —H or —C1-C6alkyl optionally substituted with one or more halogen.
Embodiment 49. A compound selected from Table 1.
Embodiment 50. The compound of embodiment 49, wherein the compound is (2R)-2-hydroxy-2-phenyl-1-[5-(pyridine-2-sulfonyl)-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl]ethan-1-one.
Embodiment 51. The compound of any one of embodiments 1-50, wherein the compound is a PKR Activating Compound having an AC50 value≤40 μM in the assay of Example 24.
Embodiment 52. The compound of any one of embodiments 1-51, wherein the compound is a PKR Activating Compound having an AC50 value≤1.0 μM in the assay of Example 24.
Embodiment 53. The compound of any one of embodiments 1-52, wherein the compound is a PKR Activating Compound having an AC50 value≤0.1 μM in the assay of Example 24.
Embodiment 54. A pharmaceutically composition, comprising a compound of any one of embodiments 1-53, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
This application is a National Stage application of International Application No. PCT/US2019/051831, filed Sep. 19, 2019, which claims priority to and the benefit of U.S. Provisional Application No. 62/733,546, filed Sep. 19, 2018, the entire contents of each of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/051831 | 9/19/2019 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2020/061255 | 3/26/2020 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4602093 | Baldwin et al. | Jul 1986 | A |
| 4918073 | Ruger et al. | Apr 1990 | A |
| 5030631 | Bauer | Jul 1991 | A |
| 5037467 | Cho et al. | Aug 1991 | A |
| 5059605 | Clough et al. | Oct 1991 | A |
| 5089621 | Kim et al. | Feb 1992 | A |
| 5091384 | Kim et al. | Feb 1992 | A |
| 5180719 | White et al. | Jan 1993 | A |
| 5250544 | Lavielle et al. | Oct 1993 | A |
| 5336772 | Saiki et al. | Aug 1994 | A |
| 5480899 | Yano et al. | Jan 1996 | A |
| 5672601 | Cignarella | Sep 1997 | A |
| 5714625 | Hada et al. | Feb 1998 | A |
| 5747502 | Hanaoka et al. | May 1998 | A |
| 5962703 | Moszner et al. | Oct 1999 | A |
| 6214879 | Abraham et al. | Apr 2001 | B1 |
| 6534501 | Abraham et al. | Mar 2003 | B2 |
| 6710052 | Pease et al. | Mar 2004 | B2 |
| 6878715 | Klein et al. | Apr 2005 | B1 |
| 7138401 | Kasibhatla et al. | Nov 2006 | B2 |
| 7160885 | Currie et al. | Jan 2007 | B2 |
| 7875603 | Rathinavelu et al. | Jan 2011 | B2 |
| 8501953 | Salituro et al. | Aug 2013 | B2 |
| 8552050 | Cantley et al. | Oct 2013 | B2 |
| 8692001 | Becker et al. | Apr 2014 | B2 |
| 8742119 | Salituro et al. | Jun 2014 | B2 |
| 8785450 | Salituro et al. | Jul 2014 | B2 |
| 8841305 | Thomas et al. | Sep 2014 | B2 |
| 8877791 | Cantley et al. | Nov 2014 | B2 |
| 8889667 | Salituro et al. | Nov 2014 | B2 |
| 8952171 | Xu et al. | Feb 2015 | B2 |
| 9012450 | Metcalf et al. | Apr 2015 | B2 |
| 9018210 | Metcalf et al. | Apr 2015 | B2 |
| 9108921 | Cianchetta et al. | Aug 2015 | B2 |
| 9181231 | Su | Nov 2015 | B2 |
| 9221792 | Salituro et al. | Dec 2015 | B2 |
| 9248199 | Metcalf | Feb 2016 | B2 |
| 9328077 | Salituro et al. | May 2016 | B2 |
| 9394257 | Ho et al. | Jul 2016 | B2 |
| 9422279 | Metcalf et al. | Aug 2016 | B2 |
| 9458132 | Cianchetta et al. | Oct 2016 | B2 |
| 9458139 | Xu et al. | Oct 2016 | B2 |
| 9604999 | Harris et al. | Mar 2017 | B2 |
| 9708267 | Boxer et al. | Jul 2017 | B2 |
| 9744145 | Liu et al. | Aug 2017 | B1 |
| 9776960 | Xu et al. | Oct 2017 | B2 |
| 9802900 | Li et al. | Oct 2017 | B2 |
| 9957250 | Metcalf et al. | May 2018 | B2 |
| 9981939 | Metcalf et al. | May 2018 | B2 |
| 10004725 | Dufu et al. | Jun 2018 | B2 |
| 10017491 | Metcalf et al. | Jul 2018 | B2 |
| 10034879 | Metcalf et al. | Jul 2018 | B2 |
| 10077249 | Li et al. | Sep 2018 | B2 |
| 10100040 | Li et al. | Oct 2018 | B2 |
| 10100043 | Metcalf et al. | Oct 2018 | B2 |
| 10208052 | Zheng et al. | Feb 2019 | B1 |
| 10266551 | Li et al. | Apr 2019 | B2 |
| 10315991 | Xu et al. | Jun 2019 | B2 |
| 10377741 | Metcalf et al. | Aug 2019 | B2 |
| 10435393 | Xu et al. | Oct 2019 | B2 |
| 10450269 | Xu et al. | Oct 2019 | B1 |
| 10472371 | Zheng et al. | Nov 2019 | B2 |
| 10493035 | Dalziel et al. | Dec 2019 | B2 |
| 10577345 | Li et al. | Mar 2020 | B2 |
| 10675274 | Ericsson et al. | Jun 2020 | B2 |
| 10683285 | Li | Jun 2020 | B2 |
| 10695330 | Li et al. | Jun 2020 | B2 |
| 11001588 | Lancia, Jr. et al. | May 2021 | B2 |
| 20040077648 | Timmer et al. | Apr 2004 | A1 |
| 20040102458 | Chiosis et al. | May 2004 | A1 |
| 20050002861 | Krause et al. | Jan 2005 | A1 |
| 20050049263 | Kasibhatla et al. | Mar 2005 | A1 |
| 20050059663 | Martin et al. | Mar 2005 | A1 |
| 20050181305 | Shibuya | Aug 2005 | A1 |
| 20050256103 | Suzuki et al. | Nov 2005 | A1 |
| 20060074121 | Chen et al. | Apr 2006 | A1 |
| 20060211737 | Huang et al. | Sep 2006 | A1 |
| 20070015752 | Hangauer, Jr. | Jan 2007 | A1 |
| 20070270433 | Brinkman et al. | Nov 2007 | A1 |
| 20080058315 | Cai et al. | Mar 2008 | A1 |
| 20080184495 | Brun et al. | Aug 2008 | A1 |
| 20080253965 | Chiosis et al. | Oct 2008 | A1 |
| 20080269234 | Gandhi et al. | Oct 2008 | A1 |
| 20090042966 | Coleman et al. | Feb 2009 | A1 |
| 20090163545 | Goldfarb | Jun 2009 | A1 |
| 20090291921 | Jabri et al. | Nov 2009 | A1 |
| 20100029575 | Junien et al. | Feb 2010 | A1 |
| 20100120863 | Biftu et al. | May 2010 | A1 |
| 20100144594 | Zoller et al. | Jun 2010 | A1 |
| 20100144722 | Alexander et al. | Jun 2010 | A1 |
| 20100152157 | Puech et al. | Jun 2010 | A1 |
| 20100179154 | Almario Garcia et al. | Jul 2010 | A1 |
| 20100216774 | Bender et al. | Aug 2010 | A1 |
| 20100324030 | Dale et al. | Dec 2010 | A1 |
| 20110059089 | Swagemakers et al. | Mar 2011 | A1 |
| 20110085969 | Rollo et al. | Apr 2011 | A1 |
| 20110104054 | Chiosis et al. | May 2011 | A1 |
| 20120252818 | Chiosis et al. | Oct 2012 | A1 |
| 20130109684 | Blagg et al. | May 2013 | A1 |
| 20130116430 | Fujiwara et al. | May 2013 | A1 |
| 20130155489 | Kato et al. | Jun 2013 | A1 |
| 20130190315 | Metcalf et al. | Jul 2013 | A1 |
| 20130190316 | Metcalf et al. | Jul 2013 | A1 |
| 20140228360 | Duncan et al. | Aug 2014 | A1 |
| 20140242602 | Chiosis et al. | Aug 2014 | A1 |
| 20150246025 | Desai | Sep 2015 | A1 |
| 20160106728 | Shen et al. | Apr 2016 | A1 |
| 20160200681 | Yu et al. | Jul 2016 | A1 |
| 20170121338 | Zhang et al. | May 2017 | A1 |
| 20170216434 | Hines et al. | Aug 2017 | A1 |
| 20170217964 | Li | Aug 2017 | A1 |
| 20180215765 | Di Giorgio et al. | Aug 2018 | A1 |
| 20190218221 | Zheng et al. | Jul 2019 | A1 |
| 20200031839 | Zheng et al. | Jan 2020 | A1 |
| 20200069643 | Ericsson | Mar 2020 | A1 |
| 20200085798 | Ericsson | Mar 2020 | A1 |
| 20200087309 | Lancia, Jr. | Mar 2020 | A1 |
| 20200129485 | Ericsson et al. | Apr 2020 | A1 |
| 20200253939 | Ericsson et al. | Aug 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 101812063 | Aug 2010 | CN |
| 102206217 | Oct 2011 | CN |
| 102952139 | Mar 2013 | CN |
| 103570722 | Feb 2014 | CN |
| 104736534 | Jun 2015 | CN |
| 105037367 | Nov 2015 | CN |
| 105085528 | Nov 2015 | CN |
| 105153119 | Dec 2015 | CN |
| 105254628 | Jan 2016 | CN |
| 105294694 | Feb 2016 | CN |
| 105348286 | Feb 2016 | CN |
| 106928222 | Jul 2017 | CN |
| 109912610 | Jun 2019 | CN |
| 102008010661 | Sep 2009 | DE |
| 0007529 | Feb 1980 | EP |
| 0036711 | Sep 1981 | EP |
| 0264883 | Apr 1988 | EP |
| 0273534 | Jul 1988 | EP |
| 0338372 | Oct 1988 | EP |
| 0363212 | Apr 1990 | EP |
| 0378255 | Jul 1990 | EP |
| 0424850 | May 1991 | EP |
| 0424851 | May 1991 | EP |
| 0424852 | May 1991 | EP |
| 0486022 | May 1992 | EP |
| 0520277 | Dec 1992 | EP |
| 0590415 | Apr 1994 | EP |
| 0737670 | Oct 1996 | EP |
| 1096310 | May 2001 | EP |
| 1099692 | May 2001 | EP |
| 1249233 | Oct 2002 | EP |
| 1952800 | Aug 2008 | EP |
| 3141542 | Mar 2017 | EP |
| 2797416 | Aug 2017 | EP |
| 1809MUM2013 | May 2013 | IN |
| 2013MU01809 | Mar 2015 | IN |
| S 61 200544 | Sep 1986 | JP |
| 3 13040 | Feb 1991 | JP |
| 3 275666 | Dec 1991 | JP |
| 04 054181 | Feb 1992 | JP |
| 05125050 | May 1993 | JP |
| 05 196976 | Aug 1993 | JP |
| 7 164400 | Jun 1995 | JP |
| 1 110376 | Jan 1999 | JP |
| 2001261653 | Sep 2001 | JP |
| 2003514673 | Apr 2003 | JP |
| 2004175674 | Jun 2004 | JP |
| 2007246885 | Sep 2007 | JP |
| 2007328090 | Dec 2007 | JP |
| 2008031064 | Feb 2008 | JP |
| 2008063256 | Mar 2008 | JP |
| 2009149707 | Jul 2009 | JP |
| 2009212473 | Sep 2009 | JP |
| 2010192782 | Sep 2010 | JP |
| 2011246649 | Dec 2011 | JP |
| 2012188474 | Oct 2012 | JP |
| 2012188475 | Oct 2012 | JP |
| 2013171968 | Sep 2013 | JP |
| 20110096442 | Aug 2011 | KR |
| 11379 | Jul 2018 | LB |
| 2517693 | Apr 2011 | RU |
| 2472794 | Nov 2012 | RU |
| WO 1993011106 | Jun 1993 | WO |
| WO 1993022298 | Nov 1993 | WO |
| WO 1995019353 | Jul 1995 | WO |
| WO 1998038239 | Sep 1998 | WO |
| WO 1998050364 | Nov 1998 | WO |
| WO 1999001442 | Jan 1999 | WO |
| WO 1999002493 | Jan 1999 | WO |
| WO 1999047489 | Sep 1999 | WO |
| WO 1999047516 | Sep 1999 | WO |
| WO 1999048461 | Sep 1999 | WO |
| WO 1999048490 | Sep 1999 | WO |
| WO 1999065895 | Dec 1999 | WO |
| WO 1999065901 | Dec 1999 | WO |
| WO 2000004023 | Jan 2000 | WO |
| WO 2000021951 | Apr 2000 | WO |
| WO 2000053591 | Sep 2000 | WO |
| WO 2001010842 | Feb 2001 | WO |
| WO 2001032764 | May 2001 | WO |
| WO 2001043744 | Jun 2001 | WO |
| WO 2001053288 | Jul 2001 | WO |
| WO 2001057037 | Aug 2001 | WO |
| WO 2001085728 | Nov 2001 | WO |
| WO 2002030358 | Apr 2002 | WO |
| WO 2002034754 | May 2002 | WO |
| WO 2002060902 | Aug 2002 | WO |
| WO 2002076989 | Oct 2002 | WO |
| WO 2002095063 | Nov 2002 | WO |
| WO 2003015769 | Feb 2003 | WO |
| WO 2003037860 | May 2003 | WO |
| WO 2003063794 | Aug 2003 | WO |
| WO 2003067332 | Aug 2003 | WO |
| WO 2003084948 | Oct 2003 | WO |
| WO 2004002490 | Jan 2004 | WO |
| WO 2004007770 | Jan 2004 | WO |
| WO 2004009600 | Jan 2004 | WO |
| WO 2004013144 | Feb 2004 | WO |
| WO 2004014374 | Feb 2004 | WO |
| WO 2004014382 | Feb 2004 | WO |
| WO 2004024676 | Mar 2004 | WO |
| WO 2004080457 | Sep 2004 | WO |
| WO 2004089470 | Oct 2004 | WO |
| WO 2004089947 | Oct 2004 | WO |
| WO 2004104000 | Dec 2004 | WO |
| WO 2005000098 | Jan 2005 | WO |
| WO 2005002577 | Jan 2005 | WO |
| WO 2005009965 | Feb 2005 | WO |
| WO 2005011653 | Feb 2005 | WO |
| WO 2005011656 | Feb 2005 | WO |
| WO 2005016915 | Feb 2005 | WO |
| WO 2005023761 | Mar 2005 | WO |
| WO 2005049570 | Jun 2005 | WO |
| WO 2005058869 | Jun 2005 | WO |
| WO 2005058870 | Jun 2005 | WO |
| WO 2005058871 | Jun 2005 | WO |
| WO 2005058873 | Jun 2005 | WO |
| WO 2005058874 | Jun 2005 | WO |
| WO 2005084667 | Sep 2005 | WO |
| WO 2005094251 | Oct 2005 | WO |
| WO 2005094834 | Oct 2005 | WO |
| WO 2005103015 | Nov 2005 | WO |
| WO 2006002100 | Jan 2006 | WO |
| WO 2006009886 | Jan 2006 | WO |
| WO 2006018279 | Feb 2006 | WO |
| WO 2006018280 | Feb 2006 | WO |
| WO 2006021448 | Mar 2006 | WO |
| WO 2006023608 | Mar 2006 | WO |
| WO 2006034315 | Mar 2006 | WO |
| WO 2006038172 | Apr 2006 | WO |
| WO 2006060122 | Jun 2006 | WO |
| WO 2006084030 | Aug 2006 | WO |
| WO 2006086445 | Aug 2006 | WO |
| WO 2006099884 | Sep 2006 | WO |
| WO 2006101521 | Sep 2006 | WO |
| WO 2006110390 | Oct 2006 | WO |
| WO 2006123121 | Nov 2006 | WO |
| WO 2006130469 | Dec 2006 | WO |
| WO 2006137485 | Dec 2006 | WO |
| WO 2007006926 | Jan 2007 | WO |
| WO 2007007069 | Jan 2007 | WO |
| WO 2007019344 | Feb 2007 | WO |
| WO 2007027734 | Mar 2007 | WO |
| WO 2007042325 | Apr 2007 | WO |
| WO 2007083119 | Jul 2007 | WO |
| WO 2007087231 | Aug 2007 | WO |
| WO 2007088123 | Aug 2007 | WO |
| WO 2007097931 | Aug 2007 | WO |
| WO 2007098418 | Aug 2007 | WO |
| WO 2007126745 | Nov 2007 | WO |
| WO 2007136603 | Nov 2007 | WO |
| WO 2007138351 | Dec 2007 | WO |
| WO 2008005937 | Jan 2008 | WO |
| WO 2008019139 | Feb 2008 | WO |
| WO 2008032905 | Mar 2008 | WO |
| WO 2008057608 | May 2008 | WO |
| WO 2008083027 | Jul 2008 | WO |
| WO 2008094203 | Aug 2008 | WO |
| WO 2008115719 | Sep 2008 | WO |
| WO 2008120003 | Oct 2008 | WO |
| WO 2008135141 | Nov 2008 | WO |
| WO 2008139585 | Nov 2008 | WO |
| WO 2009001126 | Dec 2008 | WO |
| WO 2009004356 | Jan 2009 | WO |
| WO 2009025781 | Feb 2009 | WO |
| WO 2009025784 | Feb 2009 | WO |
| WO 2009063244 | May 2009 | WO |
| WO 2009077527 | Jun 2009 | WO |
| WO 2009093032 | Jul 2009 | WO |
| WO 2009112677 | Sep 2009 | WO |
| WO 2009121623 | Oct 2009 | WO |
| WO 2009136889 | Nov 2009 | WO |
| WO 2009153554 | Dec 2009 | WO |
| WO 2010002802 | Jan 2010 | WO |
| WO 2010021717 | Feb 2010 | WO |
| WO 2010028761 | Mar 2010 | WO |
| WO 2010042867 | Apr 2010 | WO |
| WO 2010058318 | May 2010 | WO |
| WO 2010092181 | Aug 2010 | WO |
| WO 2010105243 | Sep 2010 | WO |
| WO 2010108268 | Sep 2010 | WO |
| WO 2010115688 | Oct 2010 | WO |
| WO 2010118063 | Oct 2010 | WO |
| WO 2010129596 | Nov 2010 | WO |
| WO 2010132599 | Nov 2010 | WO |
| WO 2010135524 | Nov 2010 | WO |
| WO 2010151797 | Dec 2010 | WO |
| WO 2011002816 | Jan 2011 | WO |
| WO 2011002817 | Jan 2011 | WO |
| WO 2011025690 | Mar 2011 | WO |
| WO 2011037793 | Mar 2011 | WO |
| WO 2011050210 | Apr 2011 | WO |
| WO 2011050211 | Apr 2011 | WO |
| WO 2011060321 | May 2011 | WO |
| WO 2011063055 | May 2011 | WO |
| WO 2011103256 | Aug 2011 | WO |
| WO 2011116282 | Sep 2011 | WO |
| WO 2011137089 | Nov 2011 | WO |
| WO 2011146358 | Nov 2011 | WO |
| WO 2012002577 | Jan 2012 | WO |
| WO 2012007861 | Jan 2012 | WO |
| WO 2012007868 | Jan 2012 | WO |
| WO 2012007877 | Jan 2012 | WO |
| WO 2012019426 | Feb 2012 | WO |
| WO 2012019427 | Feb 2012 | WO |
| WO 2012056319 | May 2012 | WO |
| WO 2012068096 | May 2012 | WO |
| WO 2012071519 | May 2012 | WO |
| WO 2012071684 | Jun 2012 | WO |
| WO 2012080729 | Jun 2012 | WO |
| WO 2012083246 | Jun 2012 | WO |
| WO 2012088314 | Jun 2012 | WO |
| WO 2012092426 | Jul 2012 | WO |
| WO 2012092442 | Jul 2012 | WO |
| WO 2012092485 | Jul 2012 | WO |
| WO 2012151440 | Nov 2012 | WO |
| WO 2012151448 | Nov 2012 | WO |
| WO 2012151450 | Nov 2012 | WO |
| WO 2012151451 | Nov 2012 | WO |
| WO 2012151452 | Nov 2012 | WO |
| WO 2012160392 | Nov 2012 | WO |
| WO 2012160447 | Nov 2012 | WO |
| WO 2012174126 | Dec 2012 | WO |
| WO 2013003249 | Jan 2013 | WO |
| WO 2013003250 | Jan 2013 | WO |
| WO 2013021054 | Feb 2013 | WO |
| WO 2013038390 | Mar 2013 | WO |
| WO 2013056153 | Apr 2013 | WO |
| WO 2013102142 | Jul 2013 | WO |
| WO 2013102826 | Jul 2013 | WO |
| WO 2013118805 | Aug 2013 | WO |
| WO 2013126856 | Aug 2013 | WO |
| WO 2013127266 | Sep 2013 | WO |
| WO 2013155223 | Oct 2013 | WO |
| WO 2013177224 | Nov 2013 | WO |
| WO 2013184794 | Dec 2013 | WO |
| WO 2014008458 | Jan 2014 | WO |
| WO 2014014050 | Jan 2014 | WO |
| WO 2014018355 | Jan 2014 | WO |
| WO 2014023814 | Feb 2014 | WO |
| WO 2014044356 | Mar 2014 | WO |
| WO 2014048865 | Apr 2014 | WO |
| WO 2014061031 | Apr 2014 | WO |
| WO 2014062838 | Apr 2014 | WO |
| WO 2014074848 | May 2014 | WO |
| WO 2014102817 | Jul 2014 | WO |
| WO 2014118634 | Aug 2014 | WO |
| WO 2014130890 | Aug 2014 | WO |
| WO 2014139144 | Sep 2014 | WO |
| WO 2014139325 | Sep 2014 | WO |
| WO 2014139978 | Sep 2014 | WO |
| WO 2014144715 | Sep 2014 | WO |
| WO 2014150276 | Sep 2014 | WO |
| WO 2014152588 | Sep 2014 | WO |
| WO 2014172638 | Oct 2014 | WO |
| WO 2015030514 | Mar 2015 | WO |
| WO 2015036078 | Mar 2015 | WO |
| WO 2015042397 | Mar 2015 | WO |
| WO 2015048336 | Apr 2015 | WO |
| WO 2015051230 | Apr 2015 | WO |
| WO 2015054555 | Apr 2015 | WO |
| WO 2015078374 | Jun 2015 | WO |
| WO 2015093948 | Jun 2015 | WO |
| WO 2015116061 | Aug 2015 | WO |
| WO 2015130915 | Sep 2015 | WO |
| WO 2015144605 | Oct 2015 | WO |
| WO 2015172732 | Nov 2015 | WO |
| WO 2015183173 | Dec 2015 | WO |
| WO 2015192701 | Dec 2015 | WO |
| WO 2016005576 | Jan 2016 | WO |
| WO 2016005577 | Jan 2016 | WO |
| WO 2016014324 | Jan 2016 | WO |
| WO 2016014522 | Jan 2016 | WO |
| WO 2016021815 | Feb 2016 | WO |
| WO 2016044604 | Mar 2016 | WO |
| WO 2016044629 | Mar 2016 | WO |
| WO 2016044650 | Mar 2016 | WO |
| WO 2016046837 | Mar 2016 | WO |
| WO 2016047592 | Mar 2016 | WO |
| WO 2016168647 | Oct 2016 | WO |
| WO 2016181408 | Nov 2016 | WO |
| WO 2016196816 | Dec 2016 | WO |
| WO 2016201227 | Dec 2016 | WO |
| WO 2017006270 | Jan 2017 | WO |
| WO 2017050791 | Mar 2017 | WO |
| WO 2017050792 | Mar 2017 | WO |
| WO 2017191274 | Nov 2017 | WO |
| WO 2017214002 | Dec 2017 | WO |
| WO 2018049263 | Mar 2018 | WO |
| WO 2018109277 | Jun 2018 | WO |
| WO 2018175474 | Sep 2018 | WO |
| WO 2019035863 | Feb 2019 | WO |
| WO 2019035864 | Feb 2019 | WO |
| WO 2019035865 | Feb 2019 | WO |
| WO 2019099651 | May 2019 | WO |
| WO 2019104134 | May 2019 | WO |
| WO 2019113359 | Jun 2019 | WO |
| WO 2020061252 | Mar 2020 | WO |
| WO 2020061255 | Mar 2020 | WO |
| WO 2020061261 | Mar 2020 | WO |
| WO 2020061378 | Mar 2020 | WO |
| WO 2020191022 | Sep 2020 | WO |
| Entry |
|---|
| Abbady M.A., et al., Synthesis and biological activity of some new 4-(2-pyrazolin-3-yl)-, 4-(2-isoxazolin-e-yl)- and 4-(1,2,5,6-tetrahydro-2-thioxopyrimidin-4-yl)phenyl aminophenyl sulfides and sulfones., Egyptian Journal of Pharmaceutical Sciences, vol. 27, No. 1-4, (1986), Abstract Only. |
| Abraham DJ, Mehanna AS, Wireko FC, et al. “Vanillin, a potential agent for the treatment of sickle cell anemia.” Blood. 1991;77(6):1334-41. |
| Adakveo [package insert]. East Hanover, New Jersey, Novartis Pharmaceuticals Corporation (Nov. 2019), 10 pgs. |
| Agios First Quarter 2020 Financial Results (Apr. 30, 2020), pp. 1-22. |
| Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. “Hydroxyurea in sickle cell disease: drug review.” Indian J Hematol Blood Transfus. Jun. 2014, 30(2):91-96. |
| Agrawal, R. K. et al., “Hydroxyurea in Sickle Cell Disease: Drug Review”, Indian J. Hematol Blood Transfus, 30(2), pp. 91-96, (Apr.-Jun. 2014). |
| Aiuti, A. et al, Progress and prospects: gene therapy clinical trials (part 2), Gene Ther, 14(22): 1555-1563 (2007). |
| Al-Hakim, A.K. et al., 14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK, Journal of Cell Science 118 (23), pp. 5661-5673 (Aug. 2005). |
| Al-Hakim, A.K. et al., “Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33-linked polyubiquitin chains”, Biochemical Journal, 411 (2), pp. 249-260, (Feb. 2008). |
| Alves-Filho, J.C. & Palsson-Mcdermott, E.M., Pyruvate Kinase M2: A Potential Target for Regulating Inflammation, Frontiers in Immunology, 7(145): Article 145 (2016). |
| Ambrus, J. et al.,Studies on the vasoocclusive crisis of sickle cell disease. III. In vitro and in vivo effect of the pyrimido-pyrimidine derivative, RA-233: studies on its mechanism of action, J Med, 18(3-4):165-198 (1987). |
| Amer, J. et al., Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants, British Journal of Haematology, 132(1):108-113 (2006). |
| Andresen, C.A. et al., “Protein Interaction Screening for the Ankyrin Repeats and Suppressor of Cytokine Signaling (SOCS) Box (ASB) Family Identify Asb11 as a Novel Endoplasmic Reticulum Resident Ubiquitin Ligase”, The Journal of Biological Chemistry, vol 289, No. 4, pp. 2043-2054, (Jan. 24, 2014). |
| Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. “Crizanlizumab for the prevention of pain crises in sickle cell disease.” N Engl J Med. Feb. 2, 2017 376(5):429-439. |
| Atkinson, Peter J., et al., 3,4-Dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity, BioOrganic & Medicinal Chemistry Letters, 15(3), pp. 737-741 (2005). |
| Austin, Nigel E., et al., “Novel 2,3,4,5-tetrahydro-1H-3-benzazepines with high affinity and selectivity for the dopamine D3 receptor”, BioOrganic & Medicinal Chemistry Letters, 10(22), pp. 2553-2555, (2000). |
| Bailey, S.D. et al., “Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes Reduction Assessment with Ramipril and rosiglitazone Medication (DREAM) Study”, Diabetes Care, vol. 33, No. 10, pp. 2250-2254, (Oct. 2010). |
| Bakshi N, Sinha CB, Ross D, Khemani K, Loewenstein G, Krishnamurti L. “Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease.” PLoS One. Jul. 20, 2017, 12(7):e0178413. |
| Balakin, Konstantin V. et al., Comprehensive Computational Assessment of ADME Properties using Mapping Techniques, Current Drug Discovery Technologies, 2(2), pp. 99-113 (2005). |
| Banerjee, S. et al., “Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1β phosphatase complex and the SCFβTrCP E3 ubiquitin ligase”, Biochem. J. 461, pp. 233-245, (2014). |
| Banerjee, T. and Kuypers F.A., Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells, British Journal of Haematology, 124:391-402 (2004). |
| Barbier AJ, Bodie S, Connor G, et al. “Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AG-519, an allosteric activator of pyruvate kinase-R, in healthy subjects.” Blood. 2016, 128:1264. |
| Barua, A.K., et al., Chemistry and Industry Communications to the Editor 1376 24 (Oct. 1970). |
| Bennett, Eric J., et al., “Dynamics of Cullin-RING Ubiquitin Ligase Network Revealed by Systematic Quantitative Proteomics”, Cell 143, pp. 951-965, (Dec. 10, 2010). |
| Betz T, Lenz M, Joanny JF, Sykes C. “ATP-dependent mechanics of red blood cells.” Proc Natl Acad Sci USA. 2009;106(36):15320-5. |
| Beutler, E. and Gelbart, T., “Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population”, Blood, 95(11): 3585-3588 (2000). |
| Bianchi, P. and Zanella, A., “Hematologically important mutations: red cell pyruvate kinase”, (Third update), Blood Cells Mol Dis., 26(1): 47-53 (2000). |
| Biftu, T. et al., “Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes”, Journal of Medicinal Chemistry, 57, pp. 3205-3212, (2014). |
| Bouwmeester, T. et al., “A physical and functional map of the human TNF-α/NF-κB signal transduction pathway”, Nature Cell Biology, vol. 6, No. 2, pp. 97-105, (Feb. 2004). |
| Boxer, M.B. et al., “Evaluation of Substituted N,N1-Diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase”, J. Med. Chem., 53: pp. 1048-1055 (2010). |
| Brajenovic, M. et al., “Comprehensive Proteomic Analysis of Human Par Protein Complexes Reveals an Interconnected Protein Network”, The Journal of Biological Chemistry, vol. 275, No. 13, pp. 12804-12811 (Mar. 2004). |
| Brehme, M. et al., “Charting the molecular network of the drug target Bcr-Abl”, PNAS, vol. 106, No. 18, pp. 7414-7419, (May 2009). |
| Bridges, C.R., et al., “USP9X deubiquitylating enzyme maintains RAPTOR protein levels, mTORC1 signalling and proliferation in neural progenitors”, Scientific Reports 7:391, pp. 1-15, (Mar. 2017). |
| Brown, R. Clark, et al., “FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease,” Blood (2020) 136 (Supplement 1):19-20, Nov. 4, 2020. |
| Brown, R. Clark, et al., “FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease,” ASH 2020, Dec. 7, 2020. |
| Budzikiewicz, Herbert et al., “Vincetene, a benzopyrroloisoquinoline alkaloid, from Cynanchum vincetoxicum (L.) Pers. (Asclepiadaceae)”, Liebigs Annalen Der Chemie, (8), pp. 1212-1231 (1979). |
| Buontempo P, Jubin RG, Buontempo C, Real R, Kazo F, O'Brien S, Adeel F, Abuchowski A. “Pegylated carboxyhemoglobin bovine (SANGUINATE) restores RBCs roundness and reduces pain during a sickle cell vaso-occlusive crisis.” Blood. 2017, 130:969. |
| Cabrales, P. et al., “A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?”, Med Oncol., 33(7):63 (2016). |
| CAS Registry No. 1208929-16-1, Tert-Butyl 1H,2H,3H,4H,5H,6H-Pyrrolo[3,4-C]Pyrrole-2-Carboxylate Hydrochloride (Mar. 11, 2010). |
| Castilhos, L. et al., “Altered E-NTPDase/E-ADA activities and CD39 expression in platelets of sickle cell anemia patients”, Biomed Pharmacother., 79:241-246 (2016). |
| Castilhos, L. et al., “Increased oxidative stress alters nucleosides metabolite levels in sickle cell anemia”, Redox Rep., 22(6):451-459 (2017). |
| Castilhos, L. et al., “Sickle cell anemia induces changes in peripheral lymphocytes E-NTPDase/E-ADA activities and cytokines secretion in patients under treatment”, Biomedicine & Pharmacotherapy 73 (2015), pp. 102-108. |
| Castro, O., Viability and function of stored sickle erythrocytes, Transfusion, 20(6):695-703 (1980). |
| Cazzola, M., Pyruvate kinase deficiency, Haematologica, 90(1): 1-2 (2005). |
| Charache, S. et al., Effect of 2,3-Diphosphateglycerate on oxygen affinity of blood in sickle, Cell Anemia, Journal of Clinical Investigation, 49(4):806-812 (1970). |
| Chaudhary, Neelam & Maddika, Subbareddy, “WWP2-WWP1 Ubiquitin Ligase Complex Coordinated by PPM1G Maintains the Balance Between Cellular p73 and ΔNp73 Levels”, Mol. Cell. Biol. (Oct. 2014). |
| Chen, Yue et al.—Preclinical Pharmacokinetic/Pharmacodynamic Relationships for AG-348, an Investigational Small-Molecule Activator of Pyruvate Kinase, European Hematology Association, Jun. 13, 2015. |
| Cheung, Yiu-Yin et al., Solution-Phase Parallel Synthesis and SAR of Homopiperazinyl Analogs as Positive Allosteric Modulators of MGlu4, ACS Comb Sci. 13(2), pp. 159-165, (Mar. 2011). |
| Chiosis et al., Development of a Purine-Scaffold Novel Class of Hsp90 Binders that Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase, BioOrganic & Medicinal Chemistry, vol. 10, Iss 11, (Nov. 2002), pp. 3555-3564. |
| Chiou WL, Barve A. “Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats.” Pharm Res. Nov. 1998, 15(11):1792-5. |
| Chonat, S. et al.,—Improvement in Red Blood Cell Physiology in Children With Sickle Cell Anemia Receiving Voxelotor—Childrens Healthcare of Atlanta (Dec. 2019). |
| Choudhury, N.R., et al., “RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination”, BMC Biology 15:105, pp. 1-20, (2017). |
| Christensen, R.D. et al., Siblings with Severe Pyruvate Kinase Deficiency and a Complex Genotype, American Journal of Medical Genetics, Part A, (2016), pp. 2449-2452. |
| Chubukov V, Johnson K, Kosinski PA, et al. “Characterization of metabolic response to AG-348, an allosteric activator of red cell pyruvate kinase, in healthy volunteers and pyruvate kinase deficiency patients.” Poster presented at: 58th American Society of Hematology Annual Meeting and Exposition; Dec. 4, 2016; San Diego, California. http://investor.agios.com/staticfiles/e1e9fd70-c84b-4472-bff3-bef0ecf05482 Accessed Jul. 28, 2017. |
| Chung, J.Y.L. et al., “Evolution of a Manufacturing Route to Omarigliptin, a Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes”, Organic Process Research & Development, 19, pp. 1760-1768, (2015). |
| Clinical Trial Study—NCT02604433—U.S. National Library of Medicine, an Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE), Submitted Date: Nov. 13, 2015, 24 pgs. |
| ClinicalTrials.gov, NCT03815695, (v1)—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients” (Jan. 22, 2019). |
| Clinical Trials Study, NCT03815695, (v2)—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” (Mar. 13, 2019) pp. 1-5. |
| ClinicalTrials.gov, NCT03815695, (v3)—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients” (Sep. 16, 2019). |
| Clinical Trial Study—NCT03815695, (v4)—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Sep. 19, 2019 (v4), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Sep. 23, 2019 (v5), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Oct. 9, 2019 (v6), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Oct. 10, 2019 (v7), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Nov. 27, 2019 (v8), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Jan. 15, 2020 (v9 ), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Jan. 16, 2020 (v10), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Date: Feb. 21, 2020 (v11), 5 pgs. |
| Clinical Trial Study NCT03815695—U.S. National Library of Medicine, “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients,” Submitted Apr. 1, 2020, (v12), 12 pgs. |
| ClinicalTrials.gov, NCT03815695 (v13), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Jun. 15, 2020. |
| ClinicalTrials.gov, NCT03815695 (v14), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Jul. 17, 2020. |
| ClinicalTrials.gov, NCT03815695 (v15), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Aug. 19, 2020. |
| ClinicalTrials.gov, NCT03815695 (v16), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Sep. 1, 2020. |
| ClinicalTrials.gov, NCT03815695 (v17), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Sep. 18, 2020. |
| ClinicalTrials.gov, NCT03815695 (v18), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Oct. 15, 2020. |
| ClinicalTrials.gov, NCT03815695 (v19), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamices of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Study Record Versions 19—Dec. 24, 2020. |
| ClinicalTrials.gov, NCT03815695 (v20), “A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamices of FT-4202 in Healthy Volunteers and Sickle Cell Patients,” Study Record Versions 20, Jan. 8, 2021. |
| ClinicalTrials.gov, NCT04624659 (v1), “A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease,” Study Record Version 1—Nov. 5, 2020. |
| ClinicalTrials.gov, NCT04624659 (v2), “A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease,” Study Record Version 2—Nov. 10, 2020. |
| ClinicalTrials.gov, NCT04624659 (v3), “A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease,” Study Record Versions 3—Dec. 10, 2020. |
| ClinicalTrials.gov, NCT04624659 (v4), “A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease,” Study Record Versions 4, Dec. 28, 2020. |
| ClinicalTrials.gov, NCT04624659 (v5), “A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease,” Study Record Versions 5, Jan. 7, 2021. |
| ClinicalTrials.gov, NCT04624659 (v6), “A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease,” Study Record Versions 6, Jan. 14, 2021. |
| ClinicalTrials.gov, NCT04624659 (v7), “A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease,” Study Record Versions 7, Feb. 8, 2021. |
| Cloutier, P. et al., “R2TP/Prefoldin-like component RUVBL1/RUVBL2 directly interacts with ZNHIT2 to regulate assembly of U5 small nuclear ribonucleoprotein”, Nature Communications, pp. 1-14 (May 2017). |
| Cole, D.C. et al., Conformationally Constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists, BioOrganic & Medicinal Chemistry Letters, vol. 15, No. 21, (Nov. 1, 2005), pp. 4780-4785. |
| Cox, J.L., et al., “The SOX2-Interactome in Brain Cancer Cell Identifies the Requirement of MSI2 and USP9X for the Growth of Brain Tumor Cell”, PLoS One, vol. 8, Issue 5, pp. 1-13, (May 2013). |
| Croasdell, G., European Hematology Association—20th Annual Congress (Jun. 11-14, 2015—Vienna, Austria) Meeting Report, Drugs of Today (2015), 51(7),I pp. 441-445. |
| Das, A. et al., “USP9X counteracts differential ubiquitination of NPHP5 by MARCH7 and BBS11 to regulate ciliogenesis”, PLoS Genetics, pp. 1-24, (May 12, 2017). |
| Davis, Z.H., et al., “Global Mapping of Herpesvirus-Host Protein Complexes Reveals a Transcription Strategy for Late Genes”, Molecular Cell 57, pp. 349-360; (Jan. 22, 2015). |
| De Furia, F. et al., The effects of cyanate in vitro on red blood cell metabolism and function in sickle cell anemia, J Clin Invest., 51(3):566-574 (1972). |
| De Jong, K. and Kuypers, F., Sulphydryl modifications alter scramblase activity in murine sickle cell disease, British Journal of Haematology, 133(4):427-432 (2006). |
| De Rosa MC, Carelli Alinovi C, Galtieri A, Russo A, Giardina B. “Allosteric properties of hemoglobin and the plasma membrane of the erythrocyte: New insights in gas transport and metabolic modulation.” IUBMB Life. 2008, 60(2):87-93. |
| Diez, A. et al., Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression, Blood, 106:1851 (2005). |
| Diez-Silva M, Dao M, Han J, Lim CT, Suresh S. “Shape and biomechanical characteristics of human red blood cells in health and disease.” MRS Bull. May 2010, 35(5):382-8. |
| Drissi, R. et al., “Quantitative Proteomics Reveals Dynamic Interactions of the Mini chromosome Maintenance Complex (MCM) in the Cellular Response to Etoposide Induced DNA Damage”, Molecular & Cellular Proteomics, pp. 2002-2013, (2015). |
| Droxia [package insert]. Princeton, New Jersey, Bristol-Myers Squibb Company, (Dec. 2017), 28 pgs. |
| Droxia [package insert]. Princeton, New Jersey, Bristol-Myers Squibb Company (Dec. 2019), 25 pgs. |
| Dupont, S. et al., “FAM/USP9x, a Deubiquitinating Enzyme Essential for TGFβ Signaling, Controls Smad4 Monoubiquitination”, Cell, 136, pp. 123-135, (Jan. 9, 2009). |
| Dzandu JK, Johnson RM. “Membrane protein phosphorylation in intact normal and sickle cell erythrocytes.” J Biol Chem. Jul. 10, 1980 255(13):6382-6. |
| El-Sharief, A.M., et al., Some halogenated sulfonamides with biological interest, Journal of the Indian Chemical Society, vol. 61, No. 6, (1984), pp. 537-543. |
| Emam, H.A., et al., Heterocyclization of sulfamido chalcones to pyrazoline, cyanopyridone, nicotinonitrile and hydrobenzo [1,2-c] pyrazole derivatives, Journal of the Serbian Chemical Society, vol. 62, No. 7, (1997), Abstract only. |
| Endari [package insert]. Torrance, California: Emmaus Medical, Inc., (Jul. 2017), 8 pgs. |
| Endari [package insert]. Torrance, California, Emmaus Medical, Inc., (Nov. 2019), 10 pgs. |
| Ernst, A. et al., “A Strategy for Modulation of Enzymes in the Ubiquitin System”, Science, 339, pp. 1-15, (Feb. 2013). |
| Estepp, et al., Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, A PKR-Activator, in Healthy and Sickle Cell Disease Subjects, Abstract, e-Poster, European Hematology Association Open Access Library, Presentation EHA25, (May 14, 2020), 2 pgs. |
| Estepp, et al., Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Phyarmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, a PKR Activator, in Healthy and Sickle Cell Disease Subjects, Poster, EP1531, (Jun. 12, 2020), 1 pg. |
| Estepp, J.H. et al., A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy, Am J Hematol., 92:1333-1339 (2017). |
| Estepp, Jeremie H., et al., “Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, a PKR Activator, in Healthy Volunteers and Patients with Sickle Cell Disease,” Virtual meeting [poster EP1531] presented at the 25th Congress of the European Hematology Association; Jul. 11-21, 2020. |
| European Hematology Association HemaSphere Abstract Book, 15th Annual Sickle Cell & Thalassaemia & 1st EHA European Sickle Cell Conference, Oct. 26-31, 2020. |
| Fioravanti, R., et al., Synthesis and Biological Evaluation of N-substituted -3, 5-diphenyl—2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors, European Journal of Medicinal Chemistry, vol. 45, No. 12, (Dec. 1, 2010), pp. 6135-6138, XP027526583. |
| Fitch, R. W. et al., Phantasmidine: An Epibatidine Congener from the Ecuadorian Poison Frog Epipedobates anthonyi', Journal of Natural Products (2010), vol. 73, No. 3, pp. 331-337. |
| Fleischhacker, W., et al., “Heterocyclic fused naphthalene systems from thebaine. 1”, Liebigs Annalen Der Chemie, (5), pp. 844-851, (1983). |
| Fogeron, M.L. et al., “LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells”, Nature Communications, 4:1531, pp. 1-14; (2013). |
| Forma Therapeutics, Press Release, “Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD)” (Dec. 7, 2020). |
| Forma Therapeutics, Inc., Press Release—“Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study”, Mar. 30, 2021—2 pgs. |
| Frost, David A., et al., “Naturally occurring compounds related to phenalenone. V. Synthetic approaches to structures based on 8,9-dihydro-8,8,9-trimethylphenaleno [1,2-b] furan-7-one”, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), pp. 2159-2169. |
| Gaudet, P. et al., “Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium”, vol. 12, No. 5, pp. 449-462; (Aug. 2011). |
| Giannone, R.J., et al., “The Protein Network Surrounding the Human Telomere Repeat Binding Factors TRF1, TRF2, and POT1”, PLoS One, vol. 5, Issue 8, pp. 1-10, (Aug. 2010). |
| Gizi, A. et al., Assessment of oxidative stress in patients with sickle cell disease: The glutathione system and the oxidant-antioxidant status, Blood Cells Mol Dis., 46(3):220-225 (2011). |
| Gladwin, M., Adenosine recepter crossroads in sickle cell disease, Nature Medicine, 17(1):38-40, (2011). |
| Glombitza, S. et al., Adenosine causes cAMP-dependent activation of chick embryo red cell carbonic anhydrase and 2,3-DPG synthesis, American Journal of Physiology, 271(4):973-81 (1996). |
| Gomez-Bougie, P. et al., “Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction”, Biochemical and Biophysical Research Communications 413, pp. 460-464, (2011). |
| Goncharov, T. et al., “OTUB1 modulates c-IAP1 stability to regulate signaling pathways”, The EMBO Journal 32, No. 8, pp. 1103-1114, (2013). |
| Grace RF, Rose C, Layton DM, Yaish HM, Barcellini W, Galactéros F, Morton DH, Ravindranath Y, Kuo KHM, van Beers EJ, Kwiatkowski JL, Silver BA, Merica E, Kung C, Cohen M, Yang H, Hixon J, Kosinski PA, Silver L, Dang L, Yuan Z, Barbier AJ, Glader B. “Effects of AG_348, a pyruvate kinase activator, on anemia and hemolysis in patients with pyruvate kinase deficiency: Data from the DRIVE PK study”. Blood. 2016, 128:402. |
| Grace, et al., Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency, N. Engl. J. Med. 381, 10, (Sep. 5, 2019), p. 933-944. |
| Grasso, D. et al., “Zymophagy, a Novel Selective Autophagy Pathway Mediated by VMP1-USP9x-p62, Prevents Pancreatic Cell Death”, The Journal of Biological Chemistry, vol. 286, No. 10, pp. 8308-8324, (Mar. 2011). |
| Greco, T.M. et al., “Nuclear Import of Histone Deacetylase 5 by Requisite Nuclear Localization Signal Phosphorylation”, Molecular & Cellular Proteomics 10: , pp. 1-15, (2011). |
| Grou, C.P., et al., “Identification of ubiquitin-specific protease 9X (USP9X) as a deubiquitinase acting on the ubiquitin-peroxin 5 (PEX5) thioester conjugate”, J. Biol. Chem., pp. 1-24; (Feb. 27, 2012). |
| Habata, S. et al., “BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer”, International Journal of Oncology 49: pp. 402-410, (2016). |
| Han, K.J. et al., “Ubiquitin-specific Protease 9x Deubiquitinates and Stabilizes the Spinal Muscular Atrophy Protein—Survival Motor Neuron”, J. Biol. Chem., pp. 1-22, (Oct. 2012). |
| Hanson, D. et al., “Identifying biological pathways that underlie primordial short stature using network analysis”, Journal of Molecular Endocrinology, pp. 333-344, (2014). |
| Harada, R. et al., “Structure of pristimerine, a quinonoid triterpene”, Tetrahedron Letters, pp. 603-607, (1962). |
| Harayama, Takashi et al., “Novel synthesis of naphthobenzazepines from N-bromobenzylnaphthylamines by regioselective C—H activation utilizing the intramolecular coordination of an amine to Pd”, Synlett, (8), pp. 1141-1144, (2003). |
| Hauri, S. et al., “Interaction proteome of human Hippo signaling: modular control of the co-activator YAP1”, Molecular Systems Biology, 9: 713, pp. 1-16 (Nov. 2013). |
| Havugimana, P. et al., “A Census of Human Soluble Protein Complexes”, Cell 150, pp. 1068-1081, (Aug. 2012). |
| Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. “Spontaneous oxygen radical generation by sickle erythrocytes.” J Clin Invest. 1982, 70(6):1253-9. |
| Hein, M.Y., et al., “A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances”, Cell 163, pp. 712-723, (Oct. 2015). |
| Hierso, R. et al., Effects of oxidative stress on red blood cell rheology in sickle cell patients, British Journal of Haematology, 166(4):601-606 (2014). |
| Homan, C.C. et al., “Mutations in USP9X Are Associated with X-linked Intellectual Disability and Disrupt Neuronal Cell Migration and Growth”, The American Journal of Human Genetics 94, pp. 470-478, (Mar. 2014). |
| Hoppe CC, Inati AC, Brown C, et al. “Initial results from a cohort in a phase 2a study (GBT440-007) evaluating adolescents with sickle cell disease treated with multiple doses of GBT440, a HbS polymerization inhibitor.” Blood. 2017:130(Suppl 1): 689. |
| Husain, M.I., et al., Synthesis of some new N-[4-(acetyl/phenyl-5-arylpyrazolin-3-yl)phenyl]arylsulfonamides as oral hypoglycemic agents, Indian Drugs, vol. 24, No. 4, (1987), Abstract only. |
| Huttlin, E. L., et al., “The BioPlex Network: A Systematic Exploration of the Human Interactome”, Cell 162, pp. 425-440, (Jul. 2015). |
| Huttlin, E.L., et al., “Architecture of the human interactome defines protein communities and disease networks”, Nature, pp. 1-35, (May 2017). |
| Hydrea [package insert]. Princeton, New Jersey, Bristol-Myers Squibb Company (Jul. 2019), 29 pgs. |
| Imamura K, Tanaka T. “Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I Electrophoretic studies.” J Biochem. 1972, 71:1043-51. |
| Imamura K, Tanaka T. “Pyruvate kinase isozymes from rat.” Methods Enzymol. 1982, 90:150-65. |
| International Search Report and Written Opinion for PCT/US2019/051831, dated Dec. 6, 2019 (Dec. 6, 2019). |
| Iwasaki, Tameo et al., “Novel Selective PDE IV Inhibitors as Antiasthmatic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3-bis (hydroxymethyl) naphthalene Lignans”, Journal of Medicinal Chemistry (1996), pp. 2696-2704. |
| Jendralla, H. et al., Synthesis of 1,2,3,4,5,6-Hexahydropyrrolo[3,4-c]pyrrole dihydrobromide and 1,2,3,5-Tetrahydro-2-[(4-Methyl-Phenyl)Sulfonyl]Pyrrolo[3,4-c]Pyrrole, Heterocycles, 41(6): 1291-1298 (1995). |
| Jin, Y. et al., Effects of gamma irradiation on red cells from donors with sickle cell trait, Transfusion, 37(8):804-808 (1997). |
| Johansen, L.D., et al., “IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration”, Journal of Cell Science 121, pp. 854-864, (Dec. 2007). |
| Jones, M.H., et al., “The Drosophila developmental gene fat facets has a human homologue in Xp11.4 which escapes X-inactivation and has related sequences on Yq11.2”, Human Molecular Genetics, vol. 5, No. 11, pp. 1695-1701, (Aug. 1996). |
| Jorgensen, Eugene C., et al., “Thyroxine analogs. 20. Substituted 1- and 2-naphthyl ethers of 3,5-diiodotyrosine”, Journal of Medicinal Chemistry 14(11), pp. 1023-1026, (1971). |
| Joshi, B., et al., Indian J. Chem., Sect. B (1983), 22B(2), Abstract only. Chemical Abstract No. 99:105146 |
| Joshi, P., et al., “The functional interactome landscape of the human histone deacetylase family”, Molecular Systems Biology 9, 672, (2013). |
| Kalai, T. et al., Synthesis of Pyrroline Nitroxide Annulated Carbocycles and Heterocycles, Synthesis No. 6, pp. 831-837 (2000). |
| Kalfa, et al., FORMA Therapeutics, Inc., Watertown, MA, Power Pointe Presentation, Dated Nov. 6, 2019 , Phase 1 Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FT-4202, an Allosteric activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects, 15 pgs. |
| Kalfa, T. A. et al., “Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, a PKR Activator, in Healthy and Sickle Cell Diseases Subjects”, JSCDH-D-20-0053, vol. VII, Pub. Date: Jun. 12, 2020; pp. 83-84. |
| Kalfa, T. et al., “Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, a PKR Activator, in Healthy and Sickle Cell Diseases Subjects”, 14th Annual Sickle Cell Disease Research and Educational Symposium/43rd National Sickle Cell Disease Scientific Meeting (Sep. 23-25, 2020). |
| Kalfa, T.A. et al., “616 Phase 1 Single (SAD) and Julotiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects”, (Nov. 2019). |
| Kaltenbach, L.S., et al., “Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration”, PLoS Genetics, vol. 3, Issue 5, pp. 689-708, (May 2007). |
| Kasturi, Tirumalai R., et al., “Reactions of tetrahalo-1,2-benzoquinones. III. Reaction of tetrachloro-1,2-benzoquinone withtetralones and naphthols: pathway to the condensates”, Journal of the Chemical Society C: Organic, (9), pp. 1257-1259, (1970). |
| Katzenellenbogen, R.A., et al., “NFX1-123 and Poly(A) Binding Proteins Synergistically Augment Activation of Telomerase in Human Papillomavirus Type 16 E6-Expressing Cells”, Journal of Virology, vol. 81, pp. 3786-3796, (Apr. 2007). |
| Khafagy, M.M., Synthesis of some pyrimidine and pyrazoline derivatives, Al-Azhar Bulletin of Science, vol. 3, No. 1, (1992), Abstract only. |
| Kharalkar, S.S. et al., Identification of Novel Allosteric Regulators of Human-Erythrocyte Pyruvate Kinase, Chemistry & Biodiversity, vol. 4, pp. 2603-2617 (Feb. 2007). |
| Kim H, Kosinski P, Kung C, Dang L, Chen Y, Yang H, Chen YS, Kramer J, Liu G. “A fit-for-purpose LC-MS/MS method for the simultaneous quantitation of ATP and 2,3-DPG in human K2EDTA whole blood.” J Chromatogr B Analyt Technol Biomed Life Sci. Sep 1, 2017 1061-1062:89-96. |
| Kim J, Lee H, Shin S. “Advances in the measurement of red blood cell deformability: A brief review.” J Cell Biotech. 2015;1:63-79. |
| Kim, M., et al., “Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition”, EMBO reports, vol. 17, No. 1., pp. 64-78, (Nov. 23, 2015). |
| Kimura, K., et al., “Diversification of transcriptional modulation: Large-scale identification and characterization of putative alternative promoters of human genes”, Genome Research 16, pp. 55-65, (2006). |
| Kirli, K., et al., “A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning”, eLife, pp. 1-28; (2015). |
| Knauff, E.A.H., et al., “Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene”, Human Reproduction, vol. 24, No. 9, pp. 2372-2379, (2009). |
| Kodama, K. et al., Solvent-induced dual chirality switching in the optical resolution of tropic acid via diastereomeric salt formation with (1R,2S)-2-amino-1,2-diphenylethanol, Tetrahedron 70:7923-7928 (2014). |
| Konstantinidis, Diamantis G., et al., “Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use,” Blood (2020) 136 (Supplement1):23-24, Nov. 4, 2020. |
| Konstantinidis, Diamantis G., et al., “Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use,” Presented at the 62nd American Society of Hematology (ASH) Annual Meeting, Dec. 5, 2020. |
| Kristensen, A.R., Gsponer, J. and Foster, L.J., “A high-throughput approach for measuring temporal changes in the interactome”, Nat Methods, 9(9), pp. 1-12, (2012). |
| Kuehl, G. et al., In vitro interactions of 51Cr in human red blood cells and hemolysates, Vox Sang., 40(4):260-272 (1981). |
| Kung C, Hixon J, Kosinski PA, et al. “AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.” Blood. 2017;130(11):1347-1356. |
| Kurita, R. et al., Establishment of Immortalized Human Erythroid Progenitor Cell Lines Able to Produce Enucleated Red Blood Cells, PLoS One, vol. 8, Iss.3, pp. 1-15 (Mar. 2013). |
| Kushwaha, D., et al., “USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1”, Cancer Biology & Therapy 16:3, pp. 392-401, (Mar. 2015). |
| Kwasna, D., et al., “Discovery and Characterization of ZUFSP/ZUP1, a Distinct Deubiquitinase Class Important for Genome Stability”, Molecular Cell 70, pp. 150-164, (2018). |
| Le Quesne, P.W. et al., One-Step Preparation of Tetrakis(bromomethyl)ethylene from Pinacolyl Alcohol, J. Org. Chem., 40(1): 142-143 (1975). |
| Le, Kha et al., Population pharmacokinetics and pharmacodynamics of AG-519, a pyruvate kinase activator for the treatment of pyruvate kinase deficiency, in human healthy volunteers, Agios Pharma—1263 Poster,—58th American Society of Hematology Annual Meeting and Exposition, Dec. 3-6, 2016—San Diego, CA. |
| Le, Kha et al., Population pharmacokinetics and pharmacodynamics of AG-348 in healthy human volunteers guide dose selection for the treatment of pyruvate kinase deficiency, Agios Pharma—3336 Poster,—57th American Society of Hematology Annual Meeting and Exposition, Dec. 5-8, 2015—Orlando, FL. |
| Lehrer-Graiwer J, Howard J, Hemmaway CJ, et al. “Long-term dosing in sickle cell disease subjects with GBT440, a novel HbS polymerization inhibitor.” Blood, 2016:128(22): 2488. |
| Lehrer-Graiwer, Josh et al., Long-Term Dosinig in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor, blood, 114, Hemoglobinopathies, Excluding Thalassemia—Clinical Poster II, Dec. 2, 2016. |
| Lenihan, J.A., Saha, Orthis, and Young P.W., “Proteomic analysis reveals novel ligands and substrates for LNX1 E3 ubiquitin ligase”, PLoS One, pp. 1-18; (Nov. 2017). |
| Li, X., et al., “Defining the protein-protein interaction network of the human protein tyrosine phosphatase family”, The American Society for Biochemistry and Molecular Biology, Inc., pp. 1-54, (2016). |
| Litinov RI, Weisel JW. “Role of red blood cells in haemostasis and thrombosis.” ISBT Sci Ser. Feb. 2017, 12(1):176-183. |
| Liu, X.H., et al., European Journal of Cancer, vol. 31A, No. 6, pp. 953-963, (1995). |
| Llauger et al., “Evaluation of 8-Arylsulfanyl, 8-Arylsulfoxyl, and 8-Arylsulfonyl Adenine Derivatives as Inhibitors of the Heat Shock Protein 90”, J. Med. Chem., 48 (8), pp. 2892-2905, (Mar. 25, 2005). |
| Llauger et al., “Synthesis of 8-arylsulfoxyl/sulfonyl adenines”, Tetrahedron Letters, vol. 45, Issue 52, (Dec. 20, 2004), pp. 9549-9552. |
| Lochmatter, C. et al., Integrative phosphoproteomics links IL-23R signalling with metabolic adaption in lymphocytes, Scientific Reports, 6:24491 (2016). |
| Lockwood, S. et al., Endothelium-derived nitric oxide production is increased by ATP released from red blood cells incubated with hydroxyurea, Nitric Oxide, 38:1-7 (2014). |
| Loriga G. et al., Synthesis of 3,6-diazabicyclo [3.1.1]heptanes as novel ligands for the opioid receptors, Bioorganic & Medicinal Chemistry, Pergamon, GB, vol. 14, No. 3, pp. 676-691, (Feb. 1, 2006). |
| Lu, L., et al., “The HECT Type Ubiquitin Ligase NEDL2 Is Degraded by Anaphase-promoting Complex/Cyclosome (APC/C)-Cdh1, and Its Tight Regulation Maintains the Metaphase to Anaphase Transition”, The Journal of Biological Chemistry, vol. 288, No. 50, pp. 35637-35650; (Dec. 2013). |
| Lucas, et al., “Facile Synthesis of a Library of 9-Alkyl-8-benzyl-9H-purin-6-ylamine Derivatives”, J. Comb. Chem., 3 (6), pp. 518-520, (Sep. 21, 2001). |
| MacDonald, Gregor J., et al, “Design and Synthesis of trans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))-phenyl(carboxamido)cyclohexy1)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3 Receptor Antagonist”, Journal of Medicinal Chemistry, 46(23), pp. 4952-4964 (2003). |
| Macdonald, Rosemary, Red cell 2,3-diphosphoglycerate and oxygen affinity, Anaesthesia, vol. 32, pp. 544-553, (1977). |
| Martinez-Mayorga Karina et al, Ligand/kappa-opioid receptor interactions: Insights from the X-ray crystal structure, European Journal of Medicinal Chemistry, vol. 66, pp. 114-121 (May 30, 2013). |
| Mathe-Allainmat, Monique et al., “Synthesis of 2-Amido-2, 3-dihydro-1H-phanalene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors”, Journal of Medicinal Chemistry, 39(16), pp. 3089-3095, (1996). |
| McCluskey A., et al., BioOrganic & Medicinal Chemistry Letters 10 (2000), pp. 1687-1690. |
| McCluskey A., et al., Bioorganic & Medicinal Chemistry Letters 11 (2001), pp. 2941-2946. |
| McGarry, E., et al., “The deubiquitinase USP9X maintains DNA replication fork stability and DNA damage checkpoint responses by regulating CLASPIN during S-phase”, Cancerres.aacrjournals.org, pp. 1-39; (2016). |
| Metcalf B, Chuang C, Dufu K, et al. “Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin.” ACS Med Chem Lett. 2017; 8(3):321-326. |
| Meza, N.W. et al, In vitro and in vivo expression of human erythrocyte pyruvate kinase in erythroid cells: a gene therapy approach, Hum Gene Ther, 18(6):502-514 (2007). |
| Middelkoop, E. et al., Studies on sickled erythrocytes provide evidence that the asymmetric distribution of phosphatidylserine in the red cell membrane is maintained by both ATP-dependent translocation and interaction with membrane skeletal proteins, Biochimica et Biophysica Acta, 937:281-288 (1988). |
| Misra H. Bainbridge J, Berryman J, Abuchowski A, Galvez KM, Uribe LF, Hernandez AL, Sosa NR. “A phase 1b open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia.” Rev Bras Hematol Hemoter. Jan.-Mar. 2017, 39(1):20-7. |
| Miwa, S. and Fujii, H., Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes, Am J Hematol., 51(2): 122-132 (1996). |
| Moehrle, H., et al., “1,2,3,4-Tetrahydroquinolines as substrates for Mannich compounds”, Chemical Sciences, 53(7), pp. 742-752; (1998). |
| Moriyama R, Lombardo CR, Workman RF, Low PS. “Regulation of linkages between the erythrocyte membrane and its skeleton by 2,3-diphosphoglycerate.” J Biol Chem. May 25, 1993 268(15):10990-6. |
| Mouchantaf, R., et al., “The Ubiquitin Ligase Itch Is Auto-ubiquitylated in Vivo and in Vitro but Is Protected from Degradation by Interacting with the Deubiquitylating Enzyme FAM/USP9X”, The Journal of Biological Chemistry, vol. 281, No. 50, pp. 38738-38747, (Dec. 2006). |
| Murn, J. et al., “Control of a neuronal morphology program by an RNA-binding zinc finger protein, Unkempt”, Genes & Development 29, pp. 501-512, (2015). |
| Murray, R.Z., Jolly, L.A., Wood, S.A., “The FAM Deubiquitylating Enzyme Localizes to Multiple Points of Protein Trafficking in Epithelia, where It Associates with E-cadherin and β-catenin”, Molecular Biology of the Cell, vol, 15, pp. 1591-1599; (Apr. 2004). |
| Muzyamba, M. and Gibson, J., Effect of 1-chloro-2,4-dinitrobenzene on K+ transport in normal and sickle human red blood cells, Journal of Physiology, 547(3):903-911 (2003). |
| Nagai, H., et al., “Ubiquitine-like Sequence in ASK1 Plays Critical Roles in the Recognition and Stabilization by USP9X and Oxidative Stress-Induced Cell Death”, Molecular Cell 36, pp. 805-818, (Dec. 2009). |
| Nagy, Peter I., et al., “Theoretical and Experimental Study on Ion-Pair Formation and Partitioning of Organic Salts in Octanol/Water and Dichloromethane/Water Sytems”, Journal of the American Chemical Society, 122 (28), pp. 6583-6593 (2000). |
| Nam, Keun-Soo et al., “Synthesis of quinolone antimicrobial agents and their antibacterial activities,” 5 Korean J. Med. Chem. (1995), pp. 2-5. |
| Narayanan, N., Wang, Z., Li, L., and Yang, Y., “Arginine methylation of USP9X promotes its interaction with TDRD3 and its anti-apoptotic activities in breast cancer cells”, Cell Discovery 3, pp. 1-17, (2017). |
| Nathan, J.A., et al., “The Ubiquitin E3 Ligase MARCH7 is Differentially Regulated by the Deubiquitylating Enzymes USP7 and USP9X”, Traffic, 9, pp. 1130-1145, (2008). |
| Neto, E.D. et al., “Shotgun sequencing of the human transcriptome with ORF expressed sequence tags”, PNAS, vol. 97, No. 7, pp. 3491-3496, (Mar. 2000). |
| Noma, T., et al., “Stage- and sex-dependent expressions of Usp9x, an X-linked mouse ortholog of Drosophila Fat facets, during gonadal development and oogenesis in mice”, Gene Expression Patters 2, pp. 87-91, (2002). |
| O'Connor, H.F., et al., “Ubiquitin-Activated Interaction Traps (UBAITs) identify E3 ligase binding partners”, EMBO reports, vol. 16, No. 12., (2015). |
| Obach RS. “Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.” Drug Metab Dispos. Nov. 1999, 27(11):1350-9. |
| Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR. “GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.” Br J Haematol. Oct. 2016, 175(1):141-53. |
| Oliviero, G., et al., “The variant Polycomb Repressor Complex 1 component PCGF1 interacts with a pluripotency sub-network that includes DPPA4, a regulator of embryogenesis”, pp. 1-11, (2015). |
| Olsen, J.V., et al., “Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks”, Cell 127, pp. 635-648, (Nov. 2006). |
| Oski, M.D., Frank A., “The Role of Organic Phosphates in Erythrocytes on the Oxygen Dissociation of Hemoglobin,” Annals of Clinical Laboratory Science, vol. 1, No. 2 (Nov. 1970), pp. 162-176. |
| Ould Amar, A.K. et al., Assessment of qualitative functional parameters of stored red blood cells from donors with sickle cell trait (AS) or with heterozygote (AC) status, Transfus Clin Biol., 3(4):225-233 (1996). |
| Ouyang, W., et al., “β-catenin is regulated by USP9x and mediates resistance to TRAIL-induced apoptosis in breast cancer”, Oncology Reports 35, pp. 717-724, (2016). |
| Oxbryta [package insert]. San Francisco, California, Global Blood Therapeutics, Inc. (Nov. 2019), 15 pgs. |
| Oxbryta Slide Show—Jan. 2020. |
| Paemka, L., et al., “Seizures Are Regulated by Ubiquitin-specific Peptidase 9 X-linked (USP9X), a De-Ubiquitinase”, PLoS Genetics, 11(3): pp. 1-16, (Mar. 2015). |
| Palsson-Mcdermott, EM et al., Pyruvate kinase M2 regulates Hif-1a activity and IL-1β induction and is a critical determinant of the Warburg Effect in LPS-activated macrophages, Cell Metabolism, 21:65-80 (2015). |
| Papp, S.J., et al., “DNA damage shifts circadian clock time via Hausp-dependent Cry1 stabilization”, eLIFE, pp. 1-19, (2015). |
| Park, Yoon, Jin, Hyung-seung, and Liu, Yun-Cai, “Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma 1-Bcl10-Malt1 complex”, PNAS, vol. 110, No. 23, pp. 9433-9438, (Jun. 2013). |
| Pászty C. “Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias.” Curr Opin Hematol. 1997, 4(2):88-93. |
| Patel, P., et al., Synthesis of some novel pyrazoline and cyanopyridine derivatives as antimicrobial agents, II Farmaco, vol. 51, No. 1, (1996), Abstract only. |
| Pavagadhi, T.H., et al., 3-(3′-phenoxyphenylmethyl)-5-aryl-1-acetylpyrazolines, Journal of the Institution of Chemists (India), vol. 73, No. 3, (2001), Abstract only. |
| Peddaboina, C. et al., “The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition”, BMC Cancer, 12:541, pp. 1-12, (2012). |
| Perez-Mancera, P.A., et al., “The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma”, Nature, 486(7402): pp. 266-270; (Dec. 2012). |
| Platt OS. “Hydroxyurea for the treatment of sickle cell anemia.” N Engl J Med. 2008;358(13):1362-9. |
| Poillon W., & Kim, B., 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S, Blood, 76:1028-1036 (1990). |
| Poillon, W. et al., Antisickling effects of 2,3-Diphosphoglycerate Depletion, Blood, 85(11):3289-3296 (1995). |
| Poillon, W. et al., Intracellular hemoglobin S polymerization and the clinical severity of sickle cell anemia, Blood, 91:1777-1783 (1998). |
| Poillon, W. et al., The Effect of 2,3-Diphosphoglycerate on the Solubility of Deoxyhemoglobin S1, Archives of Biochemistry and Biophysics, vol. 249, No. 2, pp. 301-305, (Sep. 1986). |
| Press Release—“Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency” Dec. 4 2016—Globe Newswire. |
| Press Release—“Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency” Dec. 10, 2017—Globe Newswire. |
| PubChem SID: 440235168, modify date Feb. 25, 2021 (Feb. 25, 2021), Version 2, p. 1-7, Structure. |
| PubChem SID: 440235168, date Feb. 18, 2021 (Feb. 18, 2021), Version 1 of 2, p. 1-7, Structure. |
| PubChem CID: 135338361, create date: Dec. 15, 2018 (Dec. 15, 2018), p. 1, formula. |
| PubChem CID: 135338378, create date: Dec. 15, 2018 (Dec. 15, 2018), p. 1, formula. |
| PubChem CID: 69203074, create date: Nov. 30, 2012 (Nov. 30, 2012), pp. 1-20, compound summary. |
| PubChem CID: 69203505, create date: Nov. 30, 2012 (Nov. 30, 2012), pp. 1-20, compound summary. |
| Rab, et al., AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, Haematologica, 105:xxx, (Jan. 23, 2020). |
| Rab, M.A.E. et al., Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients, Am. J. Hematol. (2019; 94; pp. 575-584. |
| Rabai M, Detterich JA, Wenby RB, et al. “Deformability analysis of sickle blood using ektacytometry.” Biorheology. 2014;51(2-3):159-70. |
| Ramdani, G. and Langsley, G., ATP, an Extracellular Signaling Molecule in Red Blood Cells: A Messenger for Malaria?, Biomed Journal, 37(5):284-292 (2014). |
| Raththagala, M. et al., Hydroxyurea stimulates the release of ATP from rabbit erythrocytes through an increase in calcium and nitric oxide production, European Journal of Pharmacology, 645(1-3):32-38 (2010). |
| Reblozyl [package insert]. Cambridge, Massachusetts, Acceleron Pharma, Inc. (2020), 27 pgs. |
| Reblozyl [package insert]. Summit, New Jersey, Celgene Corporation (Nov. 2019), 16 pgs. |
| Rice-Evans C, Omorphos SC, Baysal E. “Cell membranes and oxidative damage.” Biochem J. Jul. 1, 1986 237(1):265-9. |
| Rosa, M. et al., Allosteric properties of hemoglobin and the plasma membrane of the erythrocyte: New insights in gas transport and metabolic modulation, Life, 60(2):87-93 (2008). |
| Ross, M.T., et al., “The DNA sequence of the human X chromosome”, Nature, 434, pp. 325-337; (Mar. 2005). |
| Rott, Ruth, et al., “α-Synuclein fate is determined by USP9X-regulated monoubiquitination”, PNAS, (2011). |
| Roy, R., et al., “hnRNPA1 couples nuclear export and translation of specific mRNAs downstream of FGF-2/S6K2 signalling”, Nucleic Acids Research, vol. 42, No. 20, pp. 12483-12497, (Oct. 2014). |
| Rush, J., et al., “Immunoaffinity profiling of tyrosine phosphorylation in cancer cells”, Nature Biotechnology, vol. 23, No. 1, pp. 94-101, (2005). |
| Sampson M, Archibong AE, Powell A, et al. “Perturbation of the developmental potential of preimplantation mouse embryos by hydroxyurea.” Int J Environ Res Public Health. 2010;7(5):2033-44. |
| Sato, Y., et al., “Ubiquitin-specific protease 9X in host cells interacts with herpes simplex virus 1 ICP0”, J. Vet. Med. Sci. 78(3), pp. 405-410; (2016). |
| Savio et al., “USP9X Controls EGFR Fate by Deubiquitinating the Endocytic Adaptor Eps15”, Current Biology 26, pp. 173-183, (Jan. 2016). |
| Schwartz, R. et al., Two distinct pathways mediate the formation of intermediate density cells and hyperdense cells from normal density sickle red blood cells, Blood, 92(12):4844-4855 (1998). |
| Schwickart, M., et al., “Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival”, Nature vol. 463, pp. 103-108; (Jan. 2010). |
| Sega, M. et al., Fluorescence assay of the interaction between hemoglobin and the cytoplasmic domain of erythrocyte membrane band 3, Blood Cells Mol Dis., 55(3):266-271 (2015). |
| Shen, G., et al., “MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X,” BMC Cancer 14:393, pp. 1-11, (2014). |
| Shrestha, Archana, et al., “Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels,” Blood (2020) 136 (Supplement 1):21-22, Nov. 4, 2020. |
| Shrestha, Archana, et al., “Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels,” Presented at the 62nd American Society of Hematology (ASH) Annual Meeting, Dec. 5, 2020. |
| Siklos [package insert]. Lannoy, France, Delpharm Lille, (May 2019), 24 pgs. |
| Siklos [package insert]. Paris, France, Addmedica, (Dec. 2017), 25 pgs. |
| Siklos [package insert]. Paris, France, Addmedica, (May 2018), 23 pgs. |
| Smidrkal, Jan., “Synthesis of fagaronine”, Collection of Czechoslovak Chemical Communications, 53(12), pp. 3184-3192, (1988). |
| Sorathiya, S.D., et al., Preparation and antimicrobial activity of 3-(p-(2′,5′-dibromobenzenesulfonamido)phenyl)-5-aryl-1H/acetyl/phenyl-2-pyrazolines, Indian Journal of Chemistry, Section B: Organic, Incl. Medicinal Chemistry, vol. 36B, No. 7, (1997), Abstract only. |
| Soupene, E. and Kuypers, F., Identification of an erythroid ATP-dependent aminophospholipid transporter, British Journal of Haematology, 133(4): 436-438 (2006). |
| Space SL, Lane PA, Pickett CK, Weil JV. “Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium.” Am J Hematol. Apr. 2000, 63(4):200-4. |
| Spinella, J.F., et al., “Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations”, Oncotarget, vol. 7, No. 40, pp. 65485-65503, (Sep. 2016). |
| Stasiuk, M. et al., Transformations of erythrocytes shape and its regulation, Postepy Biochem., 55(4):425-33 (2009). English Abstract. |
| St-Denis, N., et al., “Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators”, Cell Reports 17, pp. 2488-2501, (Nov. 2016). |
| Stebbins et al., Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent, Cell, (Apr. 1997), 89, p. 241. |
| Steinberg, Martin H., Pathophysiologically based drug treatment of sickle cell disease, Trends in Pharmacological Sciences, vol. 27, No. 4, (Apr. 2006). |
| Strausberg, R.L., et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”, PNAS vol. 99, No. 26, pp. 16899-16903, (Dec. 2002). |
| Sun, H., et al., “Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis”, Blood, (Jan. 2011). |
| Sundd, Prithu et al., Pathophysiology of Sickle Cell Disease, Annual Review of Pathology: Mechanisms of Disease, (Oct. 9, 2018), pp. 261-290. |
| Swanson, Devin M. et al., “Identification and biological evaluation of 4-(3-trifluoromethylpyridine-2-yl) piperazine-1-c arboxylic acid (5-trifluoromethylpyridin-2-yl) amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist”, Journal of Medicinal Chemistry, 48(6), pp. 1857-1872 (2005). |
| Taipale, M., et al., “A Quantitative Chaperone Interaction Network Reveals the Architecture of Cellular Protein Homeostasis Pathways”, Cell 158, pp. 434-448, (Jul. 2014). |
| Takenaka, M. et al, Isolation and characterization of the human pyruvate kinase M gene, Eur J Biochem, 198(1):101-106 (1991). |
| Talmud, P.J., et al., “Gene-centric Association Signals for Lipids and Apolipoproteins Identified via the Human CVD Bead Chip”, The American Journal of Human Genetics 85, pp. 628-642, (Nov. 2009). |
| Tanphaichitr, V.S. et al, Successful bone marrow transplantation in a child with red blood cell pyruvate kinase deficiency, Bone Marrow Transplant, 26(6):689-690 (2000). |
| Taya, S., et al., “The deubiquitinating enzyme Fam interacts with and stabilizes β-catenin”, Genes to Cells 4, pp. 757-767, (1999). |
| Taya, S., et al., “The Ras Target AF-6 is a Substrate of the Fam Deubiquitinating Enzyme”, The Journal of Cell Biology, vol. 142, No. 4, pp. 1053-1062, (Aug. 1998). |
| Telen, Marilyn, Malik, Punam, and Vercellotti, Gregory M., Therapeutic strategies for sickle cell disease: towards a multi-agent approach, Nature Reviews/Drug Discovery; (Dec. 4, 2018). |
| Terao, Y., et al., “Trifluoroacetic Acid-Catalyzed 1,3-Cycloaddition of the Simplest Iminium Ylide Leading to 3- or 3,4-Substituted Pyrrolidines and 2,5-Dihydropyrroles”, Chem. Pharm. Bull., 33(7), pp. 2762-2766, (1985). |
| Théard, D., et al., “USP9x-mediated deubiquitination of EFA6 regulates de novo tight junction assembly”, The EMBO Journal, vol. 29, No. 9, pp. 1499-1509, (2010). |
| Thein, Swee Lay, The Molecular Basis of β-Thalassemia, Cold Spring Harb Perspect Med. (2013). |
| Thompson, Alexis, M.D., M.P.H., “A Targeted Agent for Sickle Cell Disease—Changing the Protein but Not the Gene,” The New England Journal of Medicine, (Jun. 14, 2019). |
| Tian, S., et al., Yaoxue Xueba (1993), 28(11), pp. 870-875. Chemical Abstract No. 120:299229. |
| Toloczko, A., et al., “Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS kinase and Core Components of the Hippo pathway”, Cancer Research, pp. 1-37, (Jul. 2017). |
| Tripathi, Ashutoshi and Safo, Martin K., In Silico-Screening Approaches for Lead Generation: Identification of Novel Allosteric Modulators of Human-Erythrocyte Pyruvate Kinase, Allostery: Methods and Protocols, Methods in Molecular Biology, Chpt. 19, vol, 796, pp. 351-367 (2012). |
| Trivigno, D., et al., “Deubiquitinase USP9x Confers Radioresistance through Stabilization of Mcl-1 1,2”, NEO Plasia, vol. 14, No. 10, pp. 893-904, (Oct. 2012). |
| Tsai, Y.C., et al., “Functional Proteomics Establishes the Interaction of SIRT7 with Chromatin Remodeling Complexes and Expands Its Role in Regulation of RNA Polymerase | Transcription”, Molecular & Cellular Proteomics 11.5, pp. 60-76, (2012). |
| Tsutsumi H, Tani K, Fujii H, Miwa S. “Expression of L- and M-type pyruvate kinase in human tissues. Genomics.” 1988, 2(1):86-9. |
| United States Securities and Exchange Commission, Form S-1 Registration Statement, Forma Therapeutics Holdings, Inc., dated Dec. 8, 2020, 374 pages. |
| United States Securities and Exchange Commission, Form S-1, Registration Statement—Forma Therapeutics Holdings, Inc., May 29, 2020. |
| Upadhyay J., et al., Studies on pyrazolines. Part III. Preparation and antimicrobial activity of 3-(4-phenylsulfonamidophenyl)-5-aryl-1-ace tyl/phenyl-4,5-dihydropyrazoles, Journal of the Indian Chemical Society, vol. 68, No. 7, (1991), pp. 413-414. |
| Van Zweiten, R. et al., Inborn defects in the antioxidant systems of human red blood cells, Free Radio Biol Med., 67:377-386 (2014). |
| Vanderah et al, Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors, European Journal of Pharmacology, Elsevier Science, vol. 583, No. 1, pp. 62-72 (Jan. 24, 2008). |
| Varjosalo, M., et al., The Protein Interaction Landscape of the Human CMGC Kinase Group, Cell Reports 3, pp. 1306-1320, (Apr. 2013). |
| Verma, S.K. et al., Imidazole-Catalyzed Monoacylation of Symmetrical Diamines, Organic Letters, 12(19): 4232-4235 (201). |
| Vichinsky, E. et al., “A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease,” N Engl J Med. DOI: 10.1056/NEJMoa1903212 (Jun. 2019). |
| Vichinsky, E. et al., Protocol to a Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease, (Jun. 14, 2019). |
| Vichinsky, E. et al., Supplementary Appendix to a Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease, (Jun. 14, 2019). |
| Vong, Q. P., et al., “Chromosome Alignment and Segregation Regulated by Ubiquitination of Survivin”, Science, vol. 310, pp. 1499-1504, (Dec. 2, 2005). |
| Voskou S, Aslan M, Fanis P, Phylactides M, Kleanthous M. “Oxidative stress in β-thalassaemia and sickle cell disease.” Redox Biol. Dec. 2015, 6:226-39. |
| Wagner, G. et al., Red cell vesiculation—a common membrane physiologic event, J Lab Clin., 108(4):315-324 (1986). |
| Wan, C., et al., “Panorama of ancient metazoan macromolecular complexes”, Nature 525(7569), pp. 339-344, (Sep. 2015). |
| Wang, G.S., et al., Journal of Ethnopharmacology, 26 (1989), pp. 147-162. |
| Wang, H. et al., JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1a-mediated glucose metabolism, PNAS, 111(1):279-284 (2014). |
| Wang, J., et al, “TopBP1 Controls BLM Protein Level to Maintain Genome Stability”, Molecular Cell 52, pp. 667-678, (Dec. 2013). |
| Wang, Q., et al., “The X-linked Deubiquitinase USP9X Is an Integral Component of Centrosome”, The American Society for Biochemistry and Molecular Biology, Inc., pp. 1-33, (2017). |
| Wang, S. et al., “Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer”, PNAS, vol. 111, No. 11, pp. 4251-4256, (Mar. 2014). |
| Wang, S., et al., “The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer”, Oncotarget, vol. 7, No. 40, pp. 64921-64931, (2016). |
| Wang, X, et al., “Hsp90 Cochaperone Aha1 Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis”, Cell 127, pp. 803-815, (Nov. 2006). |
| Waza et al., Nature, 11, No. 10, (Oct. 2005), pp. 1088-1095. |
| Weatherall, D., The inherited diseases of hemoglobin are an emerging global health burden, Blood, 115(22): 4331-43336 (2010). |
| Wei, Wan-Guo et al., “A practical procedure for multisubstituted .beta.-naphthols and their derivatives”, Tetrahedron, 59(34), pp. 6621-6625, (2003). |
| Willcocks, J. et al., Simultaneous determination of low free Mg2+ and pH in human sickle cells using P NMR spectroscopy, The Journal of Biological Chemistry, 277(51):49911-49920 (2002). |
| Wood BL, Gibson DF, Tait JF. “Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations.” Blood., 88(5):1873-80 (Sep. 1, 1996). |
| Wood, Kenneth W., et al., “An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE),” Blood (2020) 136 (Supplement 1):19-20, Nov. 4, 2020. |
| Wood, Kenneth W., et al., “An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease,” Presented at the 62nd American Society of Hematology (ASH) Annual Meeting, Dec. 7, 2020. |
| Woods, N.T., et al., “Charting the Landscape of Tandem BRCT Domain-Mediated Protein Interactions”, Sci Signal, 5(242), pp. 1-35, (2014). |
| Wright, S.W. et al., A Convenient Preparation of Heteroaryl Sulfonamides and Sulfonyl Fluorides from Heteroaryl Thiols, J. Org. Chem., 71: 1080-1084 (2006). |
| Wu, Y., et al., “Aberrant phosphorylation of SMAD4 Thr277-mediated USP9x-SMAD4 interaction by free fatty acids promotes breast cancer matastasis”, Cancer Research, pp. 1-34, (2017). |
| Wu, Z., et al., “Targeted Ubiquitination and Degradation of G-Protein-Coupled Receptor Kinase 5 by the DDB1-CUL4 Ubiquitin Ligase Complex”, PLoS One, vol. 7, Issue 8, pp. 1-11, (Aug. 2012). |
| Xie, Y., et al., “Deubiquitinase FAM/USP9X Interacts with the E3 Ubiquitin Ligase SMURF1 Protein and Protects It from Ligase Activity-dependent Self-degradation”, The Journal of Biological Chemistry., vol. 288, No. 5, pp. 2976-2985, (Feb. 2013). |
| Xu, Z., et al., “Identification of a Deubiquitinating Enzyme as a Novel AGS3-Interacting Protein”, PLoS One, vol. 5, Issue 3, pp. 1-12, (Mar. 2010). |
| Yan, J., et al., “Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells”, Cell Death and Disease 5, pp. 1-7, (2014). |
| Yang H, Merica E, Chen Y, Cohen M, Goldwater R, Hill C, et al. “Phase I single (SAD) and multiple ascending dose (MAD) studies of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AG-348, a first-in-class allosteric activator of pyruvate kinase-R, in healthy subjects.” Blood. 2014, 124:4007. |
| Yang H, Merica E, Chen Y, et al. “Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.” Clin Pharmacol Drug Dev. Aug. 9, 2018. |
| Yang, H. et al., Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers, 8 Clin. Pharmacol. Drug Dev. 246-259 (2019). |
| Yi, S., et al., Leukemia Research, vol. 15(10), (1991), pp. 883-886. |
| You, J. and Pickart, C.M., “A HECT Domain E3 Enzyme Assembles Novel Polyubiquitin Chains”, vol. 276, No. 23, pp. 19871-19878, (2001). |
| Yu, W., et al., “Large-Scale Concatenation cDNA Sequencing”, Genome Research 7, pp. 353-358, (1997). |
| Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. “Pyruvate kinase deficiency: The genotype-phenotype association.” Blood Rev. 2007, 23:217-31. |
| Zanella A, Fermo E, Bianchi P, Valentini G. “Red cell pyruvate kinase deficiency: molecular and clinical aspects.” Br J Haematol. 2005;130(1):11-25. |
| Zhang, C., et al., “Synergistic anti-tumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1”, Molecular Cancer Therapeutics, (May 12, 2011). |
| Zhang, C., et al., “USP9X destabilizes pVHL and promotes cell proliferation”, Oncotarget, vol. 7, No. 37, pp. 60519-60534, (2016). |
| Zhang, Y & Xia, Y., Adenosine signaling in normal and sickle erythrocytes and beyond, Microbes Infect., 14(10) (2012). |
| Zhang, Y. et al., Detrimental effects of adenosine signaling in sickle cell disease, Nature Medicine, 17(1):79-87 (2011). |
| Zhang, Yongmin et al., “Organic reactions in chiral micelles. 7. The structural effects on the asymmetric oxidation of prochiral sulfides in chiral micelles”, Chinese Journal of Chemistry, (1990), pp. 89-96. |
| Zhao, Y., et al.,“Noncanonical regulation of alkylation damage resistance by the OTUD4 deubiquitinase”, EMBO Journal, vol. 34, No. 12, pp. 1687-1703, (2015). |
| Zhi et al., Hybrid Antibacterals. DNA Polymerase—Topoisomerase Inhibitors. J. Med. Chem., published on Web Jan. 25, 2006., vol. 49, pp. 1455-1465, especially p. 1456. Scheme 3, compound 4; p. 1457, Scheme 4, compound 13, p. 1462. |
| Zhou, L., et al., “The Scaffold Protein KSR1, A Novel Therapeutic Target for the Treatment of Merlin-Deficient Tumors”, Oncogene 35(26), pp. 3443-3453, (Jun. 2016). |
| Zhou, ZH et al., Phosphorus, Sulfur and Silicon and the Related Elements (1999), 152, pp. 45-52. Chemical Abstract No. 132: 180853. |
| Zhu, Tong et al., Polymer-Supported Synthesis of Pyridone-Focused Libraries as Inhibitors of Anaplastic Lymphoma Kinase, Journal of Combinatorial Chemistry, 8(3), pp. 401-409. |
| Number | Date | Country | |
|---|---|---|---|
| 20230055923 A1 | Feb 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62733546 | Sep 2018 | US |
